Most longevity routines start with the glamorous stuff: rapamycin, zone 2 cardio, a blood panel the length of a CVS receipt. Hearing rarely makes the list. 👂 That is a strange omission, because the cells that detect sound do not regenerate in humans, and every loud night out takes a withdrawal from a fixed account.

We think hearing deserves a place next to blood pressure and glucose. Not because it is a miracle intervention (it is not), but because the data link it to outcomes people care about most. Our earlier piece on habits of people who stay strong and independent after 70 already listed annual hearing tests, and the new research explains why that advice earns its spot. 🔬 Fair warning: much of this is observational, and we will say so each time it matters.

Hearing loss is the biggest modifiable dementia risk from midlife

Start with the finding that put hearing on the longevity map. The 2024 Lancet Commission on dementia prevention listed 14 modifiable risk factors, and estimated that addressing them could prevent or delay up to 45% of dementia cases. Hearing loss is on that list. A 2025 review in the Journal of Neurology describes it as the largest modifiable dementia risk factor from midlife. 🧠 The commission also noted a dose-response pattern: in all four studies that tested it, every 10 dB drop in hearing ability came with higher dementia risk.

The mechanism is debated, and we think honesty matters here. Four ideas compete:

• Hearing loss forces the brain to spend effort decoding sound, which may leave less capacity for memory

• Less sound input may cause structural changes in auditory and nearby brain regions

• Hearing loss reduces conversation, and social isolation is a separate dementia risk factor

• Or a shared cause, such as vascular damage, may drive both problems 🫀

That last possibility is why the same 2025 review titled itself with the question “cause, catalyst or consequence?” Observational data can’t settle it. A trial can.

The best trial so far is ACHIEVE, a randomized controlled trial in The Lancet of 977 adults aged 70 to 84 with untreated mild to moderate hearing loss at four US sites. It was NIH-funded and ran for three years. The intervention group (490 people) got audiologist-fitted hearing aids, counseling and ongoing support, and the control group (487) got health education. Here is the result that gets lost in the headlines: the primary outcome was negative in the full group. In a prespecified subgroup of 238 people from the ARIC heart study, who had higher baseline dementia risk, the intervention slowed cognitive decline by 48%. In the healthy volunteers, it did nothing measurable. 🔬

So we read ACHIEVE as promising but narrow: a subgroup effect over only three years. A cost analysis of the trial put the benefit at 0.28 points on the MMSE cognitive screen, which is real but modest. Every company, trial, and funding event connected to this story is tracked and searchable in LongevityHub Pro. Meanwhile, if you are over 70 and struggling to follow dinner conversation, would you rather wait for a longer trial or get tested this month?

Does hearing loss shorten life, or just travel with things that do?

The mortality data lean one way but carry a big asterisk. A 2025 PLOS One meta-analysis of cohort studies found hearing loss linked to a 21% higher risk of all-cause death (hazard ratio 1.21), 22% higher cardiovascular mortality and 11% higher cancer mortality. Audiometry-measured hearing loss showed a stronger signal than self-reported loss, with a hazard ratio of 1.28. The catch is that heterogeneity across studies was enormous (an I² above 95% for all-cause mortality), so the pooled number hides a lot of disagreement. 📉

One large US study adds a hint about treatment. In a NHANES mortality follow-up published in Lancet Healthy Longevity, audiometry-measured hearing loss carried an adjusted hazard ratio of 1.40, and regular hearing aid users had lower mortality than never-users. Observational again. People who wear hearing aids are probably more engaged with their health than people who ignore the problem.

Then there is the cautionary tale. The German Gutenberg Health Study followed 15,010 adults aged 35 to 74. Hearing loss looked terrifying in unadjusted analysis (hazard ratio 5.64), but the link vanished after full adjustment, and the authors suggest hearing loss may be an early marker of vascular dysfunction, especially diabetes, rather than an independent killer. I find that reading plausible. The cochlea has a dense, delicate blood supply, so it may show vascular trouble before your arteries do. 🧬

What that means in practice:

• Treat a hearing test as a screening tool, like a blood pressure cuff

• If hearing declines quickly, ask your doctor about blood sugar and cardiovascular risk

• Don’t assume hearing aids extend life, because nobody has shown that in a trial

• Don’t skip them either, since they help you hear, talk and stay connected 👂

Noise damage starts earlier than your audiogram shows

The World Health Organization estimates that about 1.1 billion young people are at risk of hearing loss from unsafe listening. A 2022 meta-analysis cited in coverage of that figure found that 24% of young people listen to personal devices at unsafe volumes, and 48% are exposed to unsafe noise at clubs and concerts. 🔊 The dose math is unforgiving. Around 80 dBA is considered safe for up to 40 hours a week, workplaces cap exposure at 85 dB for eight hours, and a nightclub at 100 dB is safe for roughly 15 minutes.

The more unsettling part is what happens below the radar. In mouse studies, a single noise exposure that caused only a temporary threshold shift destroyed 40 to 50% of the synapses between inner hair cells and auditory nerve fibers, and the damage did not show up on a standard hearing test. This is called cochlear synaptopathy, or “hidden hearing loss.” 🧬 The human evidence is murkier. Some electrophysiology studies in noise-exposed adults show patterns consistent with synaptopathy, while other studies found no such evidence, and a 2026 review calls for standardized diagnostic criteria. So we have a solid animal finding, a plausible human extension and no clinical test everyone trusts.

Here is the practical read: if your ears ring after a loud event, that ringing is a temporary threshold shift, and it is a warning sign, not a harmless souvenir. 💡

• Keep earbud volume at a level where you can still hear a person next to you

• Wear foam or musician’s earplugs at concerts, and keep a pair in your bag

• Use noise-canceling headphones on planes and trains so you don’t crank the volume 🎧

• Take listening breaks, and count the hours across a week, not a single evening

Loud places are hard on your heart too

A separate body of evidence shows noise harming the cardiovascular system without touching the ear at all. Road traffic, rail and aircraft noise have been tied to higher rates of ischemic heart disease and hypertension. A WHO meta-analysis of 26 studies reported a 5% higher relative risk of hypertension per 10 dB increase in road traffic noise, and an updated meta-analysis found a relative risk of 1.04 for heart failure per 10 dB. 🫀 A 2026 meta-regression in the Journal of Exposure Science & Environmental Epidemiology still finds this field producing new exposure-response estimates, which tells you the evidence is active and not yet settled.

These effects are small per decibel, and they come from long-term observational cohorts, so confounding by air pollution, income and neighborhood is a real concern. The proposed pathway is stress and sleep disruption: noise keeps the nervous system on alert and fragments sleep, and we already know both push up blood pressure. 😴 We are not claiming your quiet bedroom cuts your heart attack risk by a specific percent. We are saying the direction is consistent.

• Sleep on the quiet side of your home if you can

• Use a white noise machine or earplugs if street noise wakes you

• Choose windows and rooms with traffic in mind when you move

• Ask yourself: is your commute soundtrack calming you or just covering the roar?

A hearing plan that costs almost nothing

None of this requires a new supplement or a clinic membership. The plan is mostly boring, which is a compliment. 💡 We would build it around three moves: protect what you have, measure it, and treat loss early.

• Get a baseline audiogram, ideally in midlife, and repeat it every few years so you can see a trend

• Protect your ears at loud events and during loud hobbies, since NIHL is permanent

• Fit hearing aids early if a test shows loss, especially if you carry other dementia risk factors 🧠

• Mention hearing to your doctor, as our guide to what your doctor isn’t telling you about aging argues, because screening rarely comes up on its own

Hearing is the rare longevity target where prevention is cheap, the harm is permanent and the best trial so far used ordinary hearing aids. Some of the evidence is strong, some is early, and I would not oversell any single number in this piece. But if you could add one test to your next checkup, would you pick a hearing test? 🔬

Here is an odd fact about longevity science: some of the cleanest signals come from the least glamorous place in the body. 🦷 Your mouth is a wet, warm, bacteria-rich organ, and it has a direct line to your bloodstream every time your gums bleed. We covered the basics in our roundup of everyday habits that quietly add years, but oral health deserves its own deep look, because the data keeps getting stronger and the habits cost almost nothing.

A caveat before we start. Nearly all of this evidence is observational, which means people who floss may simply be people who also exercise, sleep and see their doctor. 🔬 We will flag that every time it matters, and we will separate the human data from the mouse data. Deal?

Floss every day, or use an interdental brush 🧬

Lead with the finding: in the Atherosclerosis Risk in Communities (ARIC) cohort, more than 6,000 US adults reported their flossing habits and were followed for 25 years. Of those, 434 had strokes. According to the American Heart Association’s summary of the analysis, flossers had a 22% lower risk of ischemic stroke, a 44% lower risk of cardioembolic stroke (clots that travel from the heart) and a 12% lower risk of atrial fibrillation. 🫀

The proposed mechanism is simple. Plaque packs into the gaps between teeth, where a brush can’t reach. The gum tissue there gets inflamed, becomes leaky, and lets bacteria and their fragments slip into circulation, which feeds the low-grade systemic inflammation that drives vascular disease. Proposed is the key word. Nobody has proven that flossing itself cuts stroke risk, and association is not cause.

The limits are real, and they matter:

• ARIC asked about flossing once, at the start, so nobody tracked whether habits changed over 25 years

• Self-reported flossing is notoriously optimistic 😅

• Flossers tend to have healthier lifestyles overall, and statistics only partly fix that

• A randomized trial of flossing against stroke does not exist, and probably never will

My read: the cost is about 90 seconds a day and the downside is zero, so this is an easy bet. If floss annoys you, interdental brushes are fine. Which one actually survives in your routine? That is the right answer.

Brush twice a day, and never skip the night 🧠

Brushing frequency has a surprisingly consistent link to dementia risk. A Korean national health insurance study followed 74,156 adults who had two oral health screenings between 2002 and 2005, then tracked them until 2019. People who raised their brushing to three or more times a day had a lower risk of dementia (adjusted hazard ratio 0.79) and of Alzheimer’s disease (0.76). People who dropped to once a day or less had a 31% higher risk of Alzheimer’s (adjusted hazard ratio 1.31), according to the PubMed record of the paper. 💡

A second Korean analysis, covering 11 years of follow-up, found that brushing and interdental cleaning stack. Brushing at least twice a day plus some interdental cleaning came with an adjusted hazard ratio of 0.75 for dementia, with no clean dose-response curve, which tells us to be careful about reading too much into the exact numbers.

Why would a toothbrush touch the brain? The leading idea is inflammation. Chronic gum infection keeps the immune system running a low fever, and systemic inflammation is linked to amyloid production and neuronal damage. Again, these are Korean registry data, so they show association, and they tell us little about whether the finding holds in other populations. Maybe people who stop brushing are also already declining.

• Brush for two minutes, twice a day, with fluoride toothpaste

• Make the night brushing the non-negotiable one, since saliva flow drops during sleep 😴

• Use an electric brush if you tend to rush

• Treat a sudden collapse in your routine, after an illness or a move, as a reason to restart quickly

Go easy on antibacterial mouthwash 💊

This one runs against what the ads taught us. Your tongue hosts bacteria that convert dietary nitrate (beets, spinach, arugula) into nitrite, which your body then turns into nitric oxide, a molecule that relaxes blood vessels. 🥬 Antibacterial rinses can wipe those bacteria out along with the bad ones.

The best-known human test is small. In a randomized crossover trial of 15 treated hypertensive adults (mean age 65), three days of antibacterial mouthwash raised systolic blood pressure by about 2.3 mmHg compared with water. That is a modest change from a short trial in a tiny group. A 2026 scoping review found the wider literature split: five studies reported blood pressure increases after mouthwash use, and four found nothing.

So we are looking at a plausible mechanism, a small effect, and mixed results. Not a reason to panic. A reason to think about why you rinse, and how often.

• If you use mouthwash every day for a fresh feeling, water or a gentle fluoride rinse does most of the job

• If a dentist prescribed chlorhexidine for gum treatment, follow the plan and ask how long to use it

• If you take blood pressure medication, mention your rinse habit at your next visit 🩺

• If you eat nitrate-rich vegetables, you give those tongue bacteria something to work with

Get your gums measured, and treat them if they are bad 🔬

A routine cleaning is not the same as a gum exam. The part that matters for longevity is the probing, where the hygienist slides a small ruler between tooth and gum and calls out numbers. In one 2026 cohort from Acta Odontologica Scandinavica, researchers followed people aged 60 and 66 for 23 years. At baseline, 16.2% had moderate-to-severe periodontitis, and 52.7% of those people died during follow-up. After adjustment, the hazard ratio for death was 1.56, with a confidence interval of 1.00 to 2.44 and a p-value of 0.050. That is right on the statistical line, so I’d call it suggestive, not settled.

Treatment data are more interesting. In a classic randomized trial of 120 patients with severe periodontitis, intensive gum treatment was compared with community-based care. The New England Journal of Medicine paper reported that intensive treatment first caused a short-term spike in systemic inflammation and worse endothelial function, then six months later left patients with better endothelial function than the control group. 🫀 Endothelial function is a surrogate marker, not a heart attack or a death, so we can’t claim lives saved. But it does suggest the gum-vascular connection is not just a statistical accident.

• Ask for your pocket depths at each visit, since 5 mm or deeper counted toward the diagnosis in the Swedish cohort

• Ask whether your gums bleed on probing

• Book a periodontal exam if you have not had one in years 🦷

• Expect to feel a bit rough for a day or two after deep cleaning, and don’t be alarmed by it

Treat tooth loss and gum bleeding as biomarkers, not as aging 🧬

We spend a lot of money on blood panels, and our guide to longevity-focused blood work makes the case for tracking what matters. Teeth deserve a line on that dashboard. A 2026 analysis in the American Journal of Epidemiology used NHANES data from 1999 to 2018 on adults aged 40 and older. People with the worst oral health profile (22 to 28 teeth lost, severe periodontitis, poor self-rated oral health, high decay scores) faced a 59% to 89% higher risk of all-cause death than those with the best profile. The authors estimated a loss of 4.6 to 6.4 years of life expectancy at age 50. That is an observational estimate, and sicker people lose more teeth, so cause and effect run in both directions.

Dementia is where the story gets contested. A dose-response meta-analysis of 14 longitudinal studies and 34,074 participants found that more tooth loss was linked to a 28% higher risk of dementia, though the link was not significant in denture users. Then there is the Porphyromonas gingivalis theory. In mice, infection with this gum bacterium produced bacterial DNA in the brain, more amyloid-beta 42 and neuroinflammation. A drug that blocks its enzymes, atuzaginstat, went into the GAIN trial of 643 adults aged 55 to 80 with mild to moderate Alzheimer’s. It missed both primary endpoints in the full group. The company, then Cortexyme and now Lighthouse Pharmaceuticals, reported a 57% slowing of cognitive decline in a prespecified subgroup with detectable P. gingivalis. That is an industry-reported subgroup finding, and a 2026 review calls the evidence “graded plausibility rather than causal certainty,” which is about right. 🧠 If this story raised questions — who else is working on this, what the trial data looks like, which investors are behind it — LongevityHub Pro is where to find the answers.

So what do we do with all of this? We keep our teeth as long as we reasonably can, and we take bleeding gums seriously.

• Count your teeth, and ask your dentist about any that are loose

• Replace missing teeth instead of living with gaps, since denture users did better in the dementia meta-analysis 🔬

• Treat persistent gum bleeding as a symptom to investigate, not a sign you are brushing too hard

• Remember that a Swedish registry study found tooth loss at dementia diagnosis did not independently predict death, so the story is not uniform

The honest summary: none of these five habits is a proven life extender, and all of them are cheap, safe and backed by a coherent mechanism. Which one are you most likely to skip, and what would it take to fix that this week?

Your pulse costs nothing to measure and takes a minute. It might also be one of the better free predictors of how long you live. 🫀

In the Paris Prospective Study I, published in Scientific Reports in 2024, researchers followed 7,976 healthy French men aged 42 to 53 for about 25 years. Men with a resting heart rate above 90 beats per minute died at an average age of 70.3. Men below 60 reached 79.3. That is a nine-year gap from a number you can check on your wrist right now. ⏱️

We think the interesting question is not whether the correlation exists. It does. The question is whether your pulse is a lever you can pull or a symptom you can read. Count your pulse for 30 seconds, double it, and keep that number in mind. 🔬

What the large cohorts and meta-analyses find

The Paris result is not a quirk of one cohort. A 2016 CMAJ meta-analysis pooled 46 prospective studies covering 1,246,203 people and 78,349 deaths. Compared with the lowest heart-rate category, people at 60 to 80 beats per minute had a 12% higher risk of death from any cause. Above 80, the relative risk reached 1.45. 🧬

A later dose-response meta-analysis in Atherosclerosis put a price on each step. Every extra 10 beats per minute went with a 17% higher all-cause mortality risk. The studies disagree a lot on the size of the effect, so read that as a direction more than a precise forecast.

• Paris Prospective Study I: 7,976 men, roughly 25 years of follow-up, a nine-year lifespan gap between pulses above 90 and below 60

• CMAJ meta-analysis: 46 cohorts, 1.2 million participants, relative risk of 1.45 above 80 bpm

• Atherosclerosis meta-analysis: 15% higher cardiovascular risk and 14% higher total cancer risk per 10 bpm

• Open Heart, July 2026: two US cohorts of young adults where a higher resting rate predicted long-term mortality

Every one of these is observational human data. The nine-year figure compares raw average lifespans, and for men still alive at the end of follow-up the Paris authors estimated lifespan from national tables. The authors declare no competing interests. We could not open the full text of the Open Heart paper, so check its funding statement before you cite it. 💡

Why would a faster pulse matter at all? The proposed mechanism is partly mechanical. Each beat sends a pressure wave through your arteries, and a March 2026 review by Dr. Éric Thorin links a high resting rate to premature wear on blood vessels. The Paris authors add an energy argument: across mammal species, small animals with fast hearts die young. Both ideas are plausible, and neither is proven in people.

Why a fast pulse might be a marker and not a cause

Here is where the story gets less tidy. Mendelian randomization uses genetic variants as a lifelong, roughly random nudge to resting heart rate, which sidesteps a lot of confounding. A 2023 analysis in Nature Communications found no evidence that genetically higher resting heart rate raises all-cause mortality. It did find a higher risk of dilated cardiomyopathy, and a lower risk of atrial fibrillation and ischemic stroke. The authors note this contradicts their own earlier genetic study. 🧬

That should slow us down. A separate stratified analysis in the AFGen consortium found that below 65 bpm, a genetically lower rate went with more atrial fibrillation. Lower is not uniformly better.

• Drug trials are mixed: ivabradine, which slows the heart without other effects, cut coronary events only in the subgroup with rates of 70 or above in the BEAUTIFUL trial, per the Paris authors’ summary

• Cohorts disagree: the Paris authors note that Whitehall II found no link between changing heart rate and mortality

• No one has tested the lever: nobody has lowered heart rate in healthy people and tracked lifespan

• Young adults get flagged too: in the larger Open Heart cohort, a high rate predicted cardiovascular and non-cardiovascular death about equally

That last pattern fits a general fitness-and-health marker better than a heart-specific pathway. 🧠 Our read: resting heart rate is a smoke detector, not the fire. A smoke detector is still worth installing.

Would you rather track a noisy, cheap marker now or wait for a trial that may never happen? We know which one we use.

What actually lowers your resting heart rate

Exercise has the best human evidence, and it comes from randomized trials. A 2018 systematic review in the Journal of Clinical Medicine found that endurance training and yoga both lowered resting rate, though the yoga estimates carry a wide confidence interval. An earlier meta-analysis of 16 trials in older adults put the drop from endurance training at about 6 bpm, or 8.4%. 💊

One caution. Exercise improves blood pressure, fitness, and glucose control at the same time, so we cannot credit the pulse itself for any added years. Our guide to zone 2 cardio covers the easy-pace training that tends to move this number.

• Endurance exercise: the most reliable lever in the trial data, with changes building over weeks to months

• Less alcohol: a wearable analysis of 20,968 people and 5,109,185 person-days found higher nighttime resting rate and lower heart rate variability after drinking, scaling with intake

• Sleep and weight: the Cleveland Clinic lists sleep quality, body weight, caffeine, and fitness among the factors that shift it

• Medications: beta blockers slow the heart and stimulants speed it up, so ask your doctor before changing anything

Oura reports from 600,000 members that drinking raised resting rate by about 4 bpm, but that is observational data from a company that sells rings. The smaller prospective smartwatch study shows the same direction, with rates returning near baseline after drinking stopped. 🔬 Which habit on that list would you change first?

How to measure it and what to do with the number

The Paris team took the radial pulse for one full minute after five minutes lying down. Copy that: rest for five minutes, count for 60 seconds, and repeat on a few mornings. A wearable does the same job overnight, and our guide to wearable metrics that matter explains which readings to trust. ⏱️

Your trend may tell you more than any single reading. In Paris, a rise of 10 bpm over five years carried a hazard ratio of 1.20 for mortality, after adjusting for baseline rate and standard risk factors. In Framingham, the eight-year figures were 1.13 in men and 1.09 in women. If you’re following this area of longevity science professionally, LongevityHub Pro gives you the structured intelligence platform to go deeper than any single article can. 📊

• Normal range: the American Heart Association calls 60 to 100 bpm normal for most adults, with very active people as low as 40

• Compare like with like: same time of day, same posture, away from caffeine and a stressful morning

• Watch the direction: a steady climb over months deserves attention even if the number stays under 100

• Know when to call a doctor: a resting rate persistently above 100, or a low rate paired with dizziness or fainting if you are not an athlete

We would not chase a specific target. The evidence supports tracking the number, building the habits that tend to lower it, and treating a rising trend as a prompt to look closer. 🫀

What is your number this morning, and what is the first habit you would change to move it?

Here’s a number worth knowing before your next physical. In a Mayo Clinic analysis of recorded doctor visits, clinicians who asked about a patient’s concerns cut in after a median of 11 seconds. The patients who got to finish needed a median of just 6 seconds. 🩺 So the problem usually isn’t that you talk too long. It’s that your opening doesn’t land fast enough to survive the interruption.

The good news: the rules of the game changed this year in your favor. The new U.S. cholesterol guideline now tells doctors to do several things the longevity crowd has been asking for. You just have to ask in their language, not the language of your favorite biohacking podcast. We’ll show you how.

Why the word longevity makes doctors brace

Start with the clock. A large study led by Hannah Neprash at the University of Minnesota used timestamps from 21 million office visits and found the average primary care exam lasts about 18 minutes. 🔬 A follow-up in JAMA Health Forum, covering more than 8 million primary care visits, linked shorter visits with more potentially inappropriate prescribing. Neprash’s own explanation was blunt: a prescription can be a fast way to make a patient feel heard.

Now add the interruption problem. The Mayo Clinic study of 112 recorded encounters, published in the Journal of General Internal Medicine, found clinicians asked about the patient’s agenda only about a third of the time. When they did ask, they interrupted in roughly two out of three visits. This was an observational analysis of real visits in Minnesota and Wisconsin, so it’s a snapshot, not a universal law. Still, it matches what most of us have felt. 🧠

Then there’s the word itself. To many physicians, longevity signals a patient about to ask for a whole-body MRI, a supplement stack, and an off-label drug in one breath. That’s not fair to you, but it’s the filter you’re walking into.

What your doctor is juggling during your visit:

• An 18-minute average exam, often with a packed schedule behind you

• Guideline-recommended care that one widely cited estimate says would take a clinician about 27 hours a day to deliver in full

• Liability and insurance rules that make “because I read about it” a weak reason to order a test

• A reasonable fear that one unexpected result leads to a cascade of follow-up scans 💊

None of this means your goals are wrong. It means your pitch needs to fit inside their constraints.

Translate your goals into guideline language

This is the single most useful move, and 2026 made it much easier. In March, the American College of Cardiology and American Heart Association released a new multisociety dyslipidemia guideline that replaces the 2018 cholesterol guideline. 🧬 Several of its recommendations line up with what longevity-minded patients already want, which means you can ask for them as standard care.

The requests with guideline backing:

• Lipoprotein(a), once in adulthood. The guideline gives this a Class I recommendation, the first time a U.S. guideline has endorsed universal Lp(a) testing. Levels of 125 nmol/L or higher count as a risk enhancer, tied to roughly 1.4-fold higher long-term risk.

• A PREVENT risk score, including 30-year risk. The new guideline prefers the AHA’s PREVENT calculator, which covers adults 30 to 79 and adds kidney and metabolic measures. The 30-year estimate applies to people 30 to 59, where a reassuring 10-year number can hide a big lifetime risk.

• ApoB, in the right context. The guideline supports ApoB to help diagnose lipid disorders and to check leftover risk in people with diabetes, high triglycerides, or cardiovascular-kidney-metabolic disease who have already hit their LDL goals.

• Selective coronary calcium scoring for men 40 and older and women 45 and older when a treatment decision is unclear.

Notice the honest wrinkle on ApoB. The longevity world often treats it as a test everyone should get. The guideline is narrower than that. If you don’t fit one of those groups, say you want ApoB “to check whether my LDL is telling the whole story,” and expect some doctors to say it’s optional. That’s a fair disagreement, not a dismissal. 🔬

One more thing we’d be remiss to skip. Several members of the guideline writing committee disclose financial ties to drug makers, including companies developing Lp(a)-lowering drugs. That’s normal for cardiology guidelines and the recommendations went through formal review, but you deserve to know it. For the full intelligence picture behind developments like this one, LongevityHub Pro has you covered.

If you want the plain-English meaning of each marker before you go, our guide on how to read a longevity blood panel without a medical degree walks through them one by one. 💊

Build a one-page agenda that survives 18 minutes

Here’s the mechanism behind why writing things down works. When you arrive with a written list, you front-load your priorities before the interruption window closes, and you stop relying on memory while sitting half-dressed on crinkly paper. 📋 Researchers call these question prompt lists, and they’ve been studied for decades.

The evidence is decent, with a caveat. A meta-analysis of 33 randomized controlled trials with 8,244 patients found that question-listing before a visit increased how many questions patients asked. A 2025 meta-analysis of 14 randomized trials in cancer care found prompt lists improved patient engagement in shared decisions. 🧠 The catch: much of this research comes from oncology and specialty clinics, not routine physicals, and the review’s own sensitivity checks found the results for question counts and visit length were not very robust. We think the idea transfers well. We just can’t promise it’s been proven in your exact setting.

How to build your one-pager:

• Lead with one sentence of goal, framed as prevention: “I want to lower my long-term heart and metabolic risk.”

• List two asks, not ten, ranked by importance, such as Lp(a) and a PREVENT 30-year risk score

• Add relevant history in bullets: family history of early heart disease, pregnancy complications, prior lab values

• Close with one question: “Is there anything in my history that changes what you’d check?”

Hand the page over at the start, not the end. Doctors can’t respond to a request they learn about as they’re reaching for the door handle. 🩺

Which two asks would make your list if you could only pick two? Writing that down is probably the hardest and most useful part of this whole exercise.

When the answer is still no

Sometimes you’ll do everything right and still hear no. That’s not always dismissal. Your doctor may know something about your history, your insurance, or the test’s false-positive rate that you don’t. 🔬 The goal is to turn a flat no into useful information.

Phrases that keep the conversation open:

• “What would change your mind?” This asks for their threshold instead of arguing about yours.

• “Can you note in my chart that I asked?” This documents the request without escalating it.

• “What’s the downside you’re worried about?” Sometimes the answer is cost or follow-up testing, which you can weigh yourself.

• “Would you revisit this at my next visit?” Guidelines change, and so do risk profiles.

If a test isn’t covered or your doctor won’t order it, you still have options. Several standard labs, including Lp(a) and ApoB, are available through direct-to-consumer services in most U.S. states, though you should bring the results back to a clinician rather than interpret them alone. 💊 And if you keep hitting walls, it might be time for a different doctor. Our guide on how to find a longevity-literate doctor covers what to look for and what to ask in a first appointment. 🧬

Have you ever been brushed off, or pleasantly surprised, when you raised this topic? We’d genuinely like to hear which phrasing worked for you.

Your next step is concrete: before your next physical, write one goal sentence and two guideline-backed asks on a single page, and hand it over in the first minute. If you’ve never had your Lp(a) measured, make that ask number one, since the 2026 guideline says every adult should have it done at least once.

Here’s the finding that should make every introvert exhale. In the biggest review of social ties and survival ever done, the thing that predicted a longer life wasn’t party count or network size. It was social integration: being a regular, known part of other people’s lives. 🧬 That’s a quiet quality. You can build it with a barista, a phone call, and a two-hour weekly commitment, no karaoke required.

We want to be careful with the title’s promise, though. No trial has proven that a book club gives you exactly the same boost as a packed social calendar. What the evidence does show is that the health payoff follows connection, and connection comes in introvert-friendly sizes. Let’s look at why, and at the rituals with actual data behind them.

Introversion isn’t the risk factor, isolation is

The anchor study is a 2010 meta-analysis in PLOS Medicine by Julianne Holt-Lunstad and colleagues at Brigham Young University. It pooled 148 studies of social relationships and mortality covering 308,849 people, and found that people with stronger social relationships had about 50% greater odds of survival over follow-up. 🔬 The pattern held across age, sex, starting health, and cause of death.

The detail most headlines skip is the one that matters for introverts. The strongest link came from complex measures of social integration, with an odds ratio of 1.91. The weakest came from simply living alone versus with others, which didn’t reach statistical significance. So the solo apartment isn’t the problem. Being unplugged from everyone is. 🧠

What about personality itself? A preregistered 2025 meta-analysis in the Journal of Personality and Social Psychology looked at personality and mortality in 569,859 people across four continents. Extraversion predicted slightly lower death risk overall, but the effect was significant only in pooled North American and Australian samples. Conscientiousness and low neuroticism told a more consistent story. 💡

Here’s how we read the evidence:

• Social integration (being known and embedded) has the strongest survival link in the Holt-Lunstad data

• Living alone on its own shows the weakest, statistically shaky link

• Extraversion as a trait shows a small, geography-dependent effect, not a universal one

• All of this comes from observational human studies, so healthier people may simply find it easier to stay connected

The scale is real, too. The WHO Commission on Social Connection estimates that loneliness accounts for roughly 871,000 deaths a year worldwide, about 100 every hour.

What disconnection does inside your body

Loneliness leaves a chemical trace in your blood. 🧬

In a 2025 study in Nature Human Behaviour, researchers from Cambridge and Fudan University measured 2,920 plasma proteins in 42,062 UK Biobank participants. Proteins tied to social isolation and loneliness clustered in inflammation, antiviral responses, and the complement system, part of your innate immune defense. More than half of those proteins also predicted cardiovascular disease, type 2 diabetes, stroke, and death over about 14 years of follow-up. 🔬

The team then used Mendelian randomization, which uses genetic variants as a natural experiment, to test direction. It suggested loneliness drives up five specific proteins, including ADM, a protein involved in the stress response and in regulating oxytocin. Those proteins partly explained the link between loneliness and heart disease, stroke, and mortality.

The mechanism, as we understand it:

• Your brain reads isolation as a threat, like being alone on the savanna

• Chronic threat keeps stress and immune systems on a low simmer of inflammation

• That simmer wears down blood vessels and metabolism over years

• Regular, safe contact with other people appears to turn the dial back down

It’s an elegant study, but it’s still observational at heart, and it can’t tell you which kind of contact lowers these proteins. 💊 For a deeper look at the stress-hormone side, our piece on how loneliness ages you faster than smoking walks through the cortisol pathway.

Small talk with strangers counts more than you’d think

This is the ritual introverts dread most, and the one that costs the least. ☕ Psychologists Gillian Sandstrom and Elizabeth Dunn tested it directly. In a small field experiment, people told to chat briefly with a barista (smile, eye contact, a short exchange) felt more positive afterward than people told to be as efficient as possible. The effect seemed to run through a sense of belonging.

Their follow-up work, published in Personality and Social Psychology Bulletin, tracked daily interactions and found that weak ties like acquaintances and familiar faces were linked to people’s social and emotional well-being, not just close friends. 🧠 Sandstrom has said she didn’t enjoy talking to strangers growing up, and that it got easier with practice. That’s the most encouraging data point in this whole article for the socially reluctant.

Low-energy ways to collect weak ties:

• Go to the same café, gym slot, or library at the same time each week, so faces become familiar

• Learn and use one name per week: the pharmacist, the dog walker, the neighbor

• Ask one small question at checkout instead of staying silent

• Pick a regular walking route where you’ll pass the same people

Honest caveat: these studies measured mood and belonging, over days, in fairly small samples. Nobody has tracked barista chats against lifespan. 🔬 We include them because belonging is the exact ingredient Holt-Lunstad’s integration measures capture. Which familiar face in your week could you say hello to by name?

One steady voice beats a crowded room

If you’d trade ten party guests for one good conversation, science has your back. 📞 In a 2021 randomized controlled trial in JAMA Psychiatry, researchers at the University of Texas at Austin enrolled 240 homebound adults through Meals on Wheels. Half got regular phone calls from young volunteers trained for about two hours in empathetic listening; half got no calls.

After just four weeks, the call group reported less loneliness, depression, and anxiety than controls. The calls were daily for the first five days, then as few as two a week. The key ingredient was simple: the caller mostly listened and let the participant choose the topic. 🧠 Physical health scores didn’t change in that short window, and the study team disclosed grant funding from the Episcopal Health Foundation, a nonprofit.

Why this format suits introverts:

• It’s one-on-one, so no group dynamics to manage

• It’s predictable, which lowers the energy cost of socializing

• It rewards listening, which many introverts already do well

• It works by phone, so you can do it in socks

The takeaway we’d draw: turn one relationship into a standing appointment. Same person, same day, every week. A recurring call removes the “should I reach out?” friction that keeps quiet people isolated. 💡 Our breakdown of how your social circle adds or subtracts years covers why the quality of that one relationship matters too.

Helping with a job to do: volunteering and side-by-side hobbies

Volunteering is the introvert’s cheat code. You get social contact with a built-in script and a reason to be there. 🔬

The strongest recent evidence is the HEAL-HOA trial, a randomized controlled trial published in The Lancet Healthy Longevity in 2025. Researchers in Hong Kong randomized 375 lonely adults aged 50 to 70 to either a structured volunteering program or a psychoeducation control. Volunteers gave about 2 hours a week for six months, delivering phone-based support to isolated seniors. The volunteers’ own loneliness dropped at six months, with medium-to-large effect sizes.

On longevity specifically, the evidence is observational. A 2020 Harvard analysis of 12,998 U.S. adults over 50 in the Health and Retirement Study found that people who volunteered 100 or more hours a year had about 44% lower odds of dying over four years than non-volunteers, after adjusting for health, personality, and prior volunteering. 🧬 That’s a big number, and healthier people are more likely to volunteer in the first place, so we’d treat it as encouraging, not proven.

Side-by-side activity is the other introvert-friendly format: people doing something together without staring at each other. Community workshops like Men’s Sheds are built on this idea, which we covered in where all the men’s friends went. The research there is mostly surveys, so it’s weaker than the trials above. If you want to watch how this evidence matures, everything we report on ends up structured, sourced, and searchable across 7 intelligence modules in LongevityHub Pro. 💊

Introvert-friendly options with a job attached:

• Phone-based befriending programs, which mirror the HEAL-HOA and Meals on Wheels models

• Library, food bank, or animal shelter shifts where the task leads the conversation

• Community gardens or repair cafés for side-by-side work

• Small book or choir groups that meet on a fixed schedule

Roughly 100 hours a year works out to about two hours a week, the same dose HEAL-HOA used. So here’s the plan: pick one weak-tie spot, one standing call, and one two-hour weekly job with other people, then keep them for three months. Which of the three will you put on your calendar first?

Your doctor wraps a cuff around your arm at almost every visit. Almost nobody hands you a squeeze gauge. That’s an odd blind spot, because in the PURE study published in The Lancet, grip strength predicted death from any cause better than systolic blood pressure did. 🤝

The test itself takes about 30 seconds: a few hard squeezes per hand on a hand dynamometer, best score wins. What that number tells you, and what it doesn’t, is the more interesting story. We think grip strength is one of the most underrated readings in longevity medicine. There’s one big asterisk, though, and we’ll get to it.

When did a doctor last ask you to squeeze anything? If the answer is “never,” you’re in the majority.

What the biggest studies actually found

The headline number comes from PURE (Prospective Urban Rural Epidemiology), an observational study that followed 139,691 adults aged 35 to 70 across 17 countries for a median of four years. 🔬 Every 5 kg drop in grip strength came with a 16% higher risk of death from any cause and a 17% higher risk of cardiovascular death. The link held across rich, middle-income, and poor countries, which is rare for a single biomarker.

A quick word on money, because it matters. PURE is funded by the Population Health Research Institute, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Ontario, and unrestricted grants from drug companies including AstraZeneca and Sanofi. None of those firms sells grip trainers, so we see no obvious conflict here. Still, you deserve to know who paid. 💊

The finding then faced a much bigger crowd. A 2018 paper in The BMJ tracked a UK Biobank cohort of 502,293 adults aged 40 to 69 for about seven years. Per 5 kg of lower grip, all-cause death risk rose 20% in women and 16% in men, after adjusting for smoking, body size, diet, deprivation, and existing disease. Measured per standard deviation, grip had a stronger link to death than either blood pressure or self-reported exercise. 📉

Here’s how the core evidence stacks up:

• PURE (2015): 139,691 people, observational, humans only, 16% higher mortality per 5 kg lower grip

• UK Biobank (2018): 502,293 people, observational, humans only, 16% to 20% higher mortality per 5 kg lower grip

• Dose-response meta-analysis (2022): 48 cohort studies and about 3.1 million people, with death risk falling in a nearly straight line as grip rose between 26 and 50 kg

• Funding: public health bodies plus unrestricted pharma grants for PURE; the Wellcome Trust, UK government, and charities for UK Biobank, with the BMJ authors declaring no conflicts

Every one of these is an observational study. Hold that thought. 🧬

Why a hand squeeze knows so much about your body

Grip strength is a stand-in. Your fingers don’t decide your lifespan, but they report on systems that help decide it. 💪

The first system is whole-body muscle strength. Research cited by the UK Biobank team shows grip and knee extension strength measure a common underlying trait, so a weak grip usually means weak legs too. Weak legs mean more falls, fewer stairs, and a slow slide toward frailty.

The second is metabolism. Skeletal muscle is the body’s main place for disposing of glucose after a meal and its main protein reserve during serious illness. When cancer, infection, or kidney disease strikes, the body draws down that reserve. More muscle means a bigger buffer. 🧠

The third is the nervous system. Force depends on motor neurons firing together in sync, so a falling grip can probably flag neural decline before other signs show up.

Then there’s the epigenetic angle. In a 2023 Health and Retirement Study analysis in the Journal of Cachexia, Sarcopenia and Muscle, University of Michigan researchers looked at 1,274 middle-aged and older adults and three DNA methylation clocks. Weaker grip went with faster epigenetic aging, both at a single time point and over follow-up. 🧬

What that study does and doesn’t show:

• Does show: people with weaker grips tend to have older-looking blood epigenomes

• Does show: the pattern held across three separate clocks, in both men and women

• Doesn’t show: that weakness causes faster aging, since income, diet, and disease could drive both

• Doesn’t show: anything about lifespan directly, because the study measured clocks, not deaths

If you want to see how grip fits next to other cheap aging metrics, our guide on how to find out your biological age at home for under $50 puts it beside PhenoAge and VO2 max.

The part headlines skip: prediction isn’t causation

Here’s the asterisk. A number that predicts death isn’t necessarily a number that causes it. 🔬

The biggest worry is reverse causation. Sickness makes you weak. Early heart failure, hidden cancer, and chronic inflammation all sap strength years before a diagnosis. So some of the grip signal is probably disease showing up in your hands first. The UK Biobank team tried to limit this by throwing out deaths in the first two years; the results held, but the authors still say they can’t rule it out. Their volunteers were also healthier than average, since only about 5.5% of invited people signed up.

Genes muddy things further. The same paper cites a heritability estimate of about 52% for grip strength, so part of your number came with your birth certificate. 🧬

A few lines of evidence push back toward a real effect:

• A 2017 Mendelian randomization study in Scientific Reports found each genetically predicted extra kilogram of grip linked to 6% lower odds of coronary artery disease, though it relied on only two genetic variants

• The dose-response pattern is smooth rather than a cliff, which fits a real biological gradient

• Strength training reliably improves grip in randomized trials, so the number is modifiable

And a few push the other way:

• No randomized trial has tested whether raising grip strength extends life

• The cancer link is shaky: PURE found no consistent association, and a 2018 meta-analysis of 11 cohorts found grip wasn’t significantly tied to cancer death

• Mark Peterson, the Michigan researcher behind the epigenetic study, has cautioned that building a weak grip won’t magically add years

If you’re following this area of longevity science professionally, LongevityHub Pro gives you the structured intelligence platform to go deeper than any single article can. For everyone else, here’s our honest read: grip strength is an excellent warning light, and a probably useful target, but it isn’t a proven lever for lifespan on its own. 💡

How to run the 30-second test at home

You need a hand dynamometer, which costs roughly $30 online. ✋ The protocol mirrors what the big studies use. PURE had participants squeeze three times with each hand and kept the best reading.

• Sit or stand with your elbow bent at 90 degrees and your upper arm tucked against your side

• Squeeze as hard as you can for about 3 seconds, then rest briefly

• Do three attempts per hand, alternating hands

• Record the highest single score from each hand

• Retest with the same device at the same time of day, since cheap dynamometers disagree with each other

Now, what counts as a good number? 📏 The UK Biobank paper used a weakness cutoff of 26 kg or less for men and 16 kg or less for women. On the other end, a 2022 SHARE study of older adults in 28 countries, published in Age and Ageing, found mortality benefits rising until about 42 kg in men and 25 kg in women, then leveling off. In people 65 and older, though, each extra kilogram kept helping. Grip also tends to fall about 1% a year after midlife, so starting high buys you room. 📉

One newer wrinkle: a 2026 UK Biobank analysis of 308,810 people looked at the gap between hands, defining asymmetry as more than a 10% difference. The authors say that gap deserves attention in risk assessment, so log both hands.

For concrete targets by age, our piece on the muscle mass target you should hit before age 50 lays out the numbers worth building toward. Try the test this week and write your score down. Did it surprise you? Tell us in the comments, because we’re curious whether our readers beat the population averages. 🤔

What actually moves the number

Good news: grip strength is stubbornly responsive to training at almost any age. 💪 A 2025 meta-analysis in Aging Clinical and Experimental Research pooled 24 randomized controlled trials with 951 adults aged 60 and over who had diagnosed sarcopenia. Resistance training significantly improved grip strength, gait speed, and knee extension strength compared with usual care.

Here’s the fun mechanistic twist. Those same trials showed no significant change in measured muscle mass. Strength went up anyway. The likely explanation is neural adaptation: your nervous system gets better at recruiting the muscle you already have, well before new muscle shows up. 🧠 That’s encouraging if you’re older and worried you’ve “lost it.” You probably haven’t lost as much as you think.

Our practical take:

• Train the whole body two or three times a week with progressively heavier loads, not just your forearms

• Add loaded carries (farmer’s walks), deadlifts, and dead hangs, which build grip as a side effect of real work

• Skip gimmicky spring grippers as your main plan; they can raise the number without improving what it measures

• Retest every 8 to 12 weeks on the same device and track the trend, not a single reading

• If you’re over 50 or coming back from injury, ease in with the approach in our injury-proof guide to strength training after 50

That gimmick point deserves a second of your attention. 🔬 If grip matters because it reflects whole-body strength, then squeezing a toy all day is like warming a thermometer with your hand. The reading improves. The room stays cold.

So here’s your next step: borrow or buy a dynamometer, do three squeezes per hand, and log your best score today. Then set a reminder to retest in 12 weeks, after a few months of honest whole-body training. Will your number go up?

Your next eye exam may already capture something your doctor is not looking for. 👁️ A retinal scan called optical coherence tomography takes 5 to 10 minutes, and a growing pile of studies links thinner retinal nerve layers to dementia diagnosed a decade or more later. We think that is one of the more interesting findings in early detection, and one of the easiest to oversell. 🧠

Here is our read. The signal is real in large datasets, the effect is modest for any one person, and we found no FDA-cleared retinal test for predicting dementia. Below, we cover what the scan measures and why the eye tells you anything about the brain, what the long-follow-up studies find, where the evidence gets shaky, and what to do with it today. Quick question before we start: do you know when you last had a dilated eye exam?

Why an eye scan says anything about your brain

The logic starts with anatomy. Because the retina and brain originate from the same neural tube, the eyes are often regarded as extensions of the brain, and the retina is the only optically accessible nervous tissue. Optical coherence tomography (OCT) is a non-invasive, rapid imaging method already widely available in ophthalmology clinics, and a scan takes only 5 to 10 minutes. It images the retina in cross-section, so researchers can measure individual layers, including the retinal nerve fiber layer (RNFL) and the ganglion cell-inner plexiform layer (GC-IPL). 🔬

Two mechanisms are proposed, and they are not mutually exclusive. The first is neurodegeneration. In an autopsy study in Acta Neuropathologica, researchers analyzed donated retina and brain tissue from 86 people and found more beta-amyloid in the retinas of people with Alzheimer’s or early cognitive decline, while microglia, the cells that clear debris, dropped by about 80% in people with cognitive problems. The second is vascular. A retinal-age score from Singapore researchers associates closely with brain imaging markers of cerebral small vessel disease and brain atrophy. So thinning may reflect lost nerve cells, damaged small vessels, or both. 🧬

Four things researchers measure:

• OCT layer thickness: RNFL and GC-IPL, the workhorse measures in the big cohorts

• OCT angiography: vessel density in the macula, with mixed results across studies

• Retinal photographs plus AI: ordinary fundus photos scored by deep learning, such as a “retinal age”

• Hyperspectral imaging: light at many wavelengths, searching for an amyloid signature, still experimental

What the long-follow-up studies find

Start with the largest clean signal. A 2025 analysis in Alzheimer’s & Dementia follows 35,433 UK Biobank participants for a median of 12.49 years, during which 392 people (1.11%) develop dementia. People in the lowest macular RNFL thickness quintile have a 64% higher risk of dementia than those in the highest (HR 1.64, 95% CI 1.17 to 2.30), and each 5-micrometer decrease goes with a 15% higher risk. APOE ε4 accounts for only 7.6% of that association, so thinning is not just a stand-in for the best-known risk gene. This is observational human data, and it excludes people with eye disease and baseline dementia. 🧠

A pooled analysis of four cohorts finds a smaller effect. Lower baseline macular RNFL thickness goes with 10% and 11% higher incidence of all-cause dementia and Alzheimer’s disease, while GC-IPL thickness is not significantly associated. An earlier UK Biobank analysis of 30,573 people (mean age about 55) finds greater GC-IPL thickness goes with lower Alzheimer’s risk (HR 0.968, 95% CI 0.938 to 0.999) over about nine years, with only 148 Alzheimer’s cases. That interval barely clears 1.0. 💊

Does it show up earlier still? The Dunedin Study looked at midlife. In 938 people assessed at age 45, narrower arterioles and wider venules go with higher scores on four established dementia-risk indexes. Note the outcome: risk scores, not dementia.

Then there is AI on ordinary photos. A 2025 study in Alzheimer’s & Dementia scores a deep-learning “retinal age,” trained to mimic the PhenoAge blood clock we cover in our guide to aging blood tests. In 510 Singapore memory-clinic patients, older retinal age predicts cognitive decline (SHR 1.34) and dementia (SHR 1.43), and in 33,495 UK Biobank participants it predicts incident dementia over 12 years (SHR 1.25). The authors declare no conflicts of interest.

The numbers side by side:

• HR 1.64: lowest versus highest RNFL quintile, 35,433 people, about 12.5 years

• 10% to 11% higher incidence: lower RNFL across four pooled cohorts

• SHR 1.25: older retinal age and incident dementia, 33,495 people, 12 years

• HR 0.968: GC-IPL thickness and Alzheimer’s risk, 30,573 people, 148 cases

Why it is a risk flag and not a diagnosis

Look back at how few people got dementia in the biggest study. With 392 cases among 35,433 people, most participants in the thinnest quintile never developed dementia during follow-up. A 64% higher relative risk on a small baseline is still a small absolute risk. 🔬

Specificity is the next problem. A systematic review of OCT findings says the value of retinal biomarkers for early detection remains uncertain because of variability and limited disease specificity. A separate review of OCT and brain MRI adds that retinal findings can occur in both dementia and non-neurocognitive conditions, which makes them hard to apply across a broad population.

The amyloid-imaging work is earlier still. In a Swedish memory-clinic study of 57 patients (35 amyloid-positive, 22 amyloid-negative), the best hyperspectral model reaches a mean AUC of 0.77, accuracy of 0.66, sensitivity of 0.73 and specificity of 0.55. A specificity of 0.55 means roughly 45% of amyloid-negative patients get flagged anyway. Several authors are affiliated with Mantis Photonics AB, a company, an industry link we want you to see. RetiSpec’s larger Bio-Hermes-002 study is an ongoing multi-site effort planning about 1,200 participants, with 387 enrolled at the time of reporting and full performance data still forthcoming, and its authors are RetiSpec employees. 🧬

Two more cautions. In the Dunedin cohort of 865 people, lower childhood IQ associates with thinner RNFL at age 45, alongside a greater decline in processing speed, so some of the thinning may be a lifelong trait rather than a sign of decline. And the University of Florida’s June 2026 study uses an AI model trained on more than 40,000 patients to predict blood pressure, smoking, alcohol use and insomnia from retinal photos. Those are risk factors, not dementia itself.

Why we would not act on a single scan:

• Low absolute risk: most people with thin layers never develop dementia in the studied window

• Overlap with other conditions: thinning is not unique to Alzheimer’s

• Modest hyperspectral accuracy: small samples, industry-linked authors

• Possible lifelong trait: part of the signal may predate any decline

If a scan told you your dementia risk was a quarter above average, what would you change on Monday?

Where regulators and blood tests fit

Regulators have moved on blood tests, not eye scans. The Alzheimer’s Association reports that the FDA’s August 24, 2026 clearance of Roche’s Elecsys pTau217 is the fourth blood-based biomarker test for Alzheimer’s the agency has cleared. The sequence: Fujirebio’s Lumipulse in May 2025, Roche’s Elecsys pTau181 in October 2025, C2N’s PrecivityAD2 in August 2026, then Elecsys pTau217. The pTau217 test, developed with Eli Lilly, is cleared for people 55 and older with signs, symptoms or complaints of cognitive decline, and it is not a stand-alone diagnostic, and an intermediate result needs further testing. 💊

So blood tests answer do you have amyloid pathology, given symptoms, while retinal tests try to answer who should we worry about earlier. Those are different jobs. As far as we can find, retinal amyloid tools are still research-stage. A National Library of Medicine overview says Optina Diagnostics’ retinal test has FDA Breakthrough Device designation but is available for research, not commercial use, and RetiSpec’s ocular test is also early-stage and not commercially available. Every company, trial, and funding event connected to this story is tracked and searchable in LongevityHub Pro. 🔬

Where each tool stands:

• Amyloid blood tests: FDA-cleared, for symptomatic adults

• Retinal OCT: routine for eye disease, not cleared to predict dementia (as far as we can find)

• Hyperspectral amyloid imaging: research use, with Breakthrough Device designation for one company

• Retinal-photo AI: validated in cohort studies, not a clinical product

What to do with this now

Nothing here requires you to buy a new test. It does suggest a few sensible moves. 🧠

First, keep your routine eye exams. The UF team notes that even regular eye exams for prescription glasses can capture retinal photos. If you already have OCT or retinal images from an eye doctor, ask for a copy. We think a baseline you can compare against later is worth more than a single reading, though no guideline tells you to do this. Researchers have also floated the idea that continuous OCT monitoring holds promise for predicting cognitive trajectories.

Second, treat retinal risk as a prompt to fix what you can. The UF model picks up blood pressure, smoking, alcohol and insomnia, all modifiable. Our piece on brain habits covers a 2025 GeroScience meta-analysis of 39 cohort studies linking insomnia to a 36% higher dementia risk, and our list of medical screenings that can add years covers checks worth scheduling.

Third, if you are 55 or older and notice memory symptoms, ask about the blood tests. Retinal screening does not replace that conversation.

What to do this month:

• Book a dilated eye exam if you are overdue, and ask whether OCT is part of it

• Request your images so you have a baseline

• Check blood pressure and sleep, the retinal-linked risk factors you can change

• Raise memory symptoms early with a clinician if you are 55 or older

Which of those four would you start with, and what is stopping you?

Get a dog, live longer. It is the kind of claim that spreads because it is pleasant to believe. 🧬 We looked at what sits underneath it: meta-analyses covering millions of people, a re-analysis that shrinks the effect, and newer cohort work that asks which animals matter. Nearly every study below is observational, so “adds years” in our title is shorthand for “goes with longer lives.” Our short version is a cautious yes. The association is real in the data, part of it is probably selection, and a plausible mechanism keeps it from looking like a statistical accident. 🔬

As you read, ask yourself a simple question: does your own pet get you moving, calm you down, or both?

The big dog studies, and what they find

The headline number comes from a 2019 meta-analysis in Circulation: Cardiovascular Quality and Outcomes. It pools 10 observational studies covering 3,837,005 people, with a mean follow-up of 10.1 years, and finds that dog ownership goes with a 24% lower risk of death from any cause (relative risk 0.76, 95% CI 0.67 to 0.86). Note the word observational. The authors say the analyses were not adjusted for confounders, and the lead author adds that they did not account for factors such as better fitness or a healthier lifestyle. She also thanks her miniature Schnauzer, Romeo, for inspiring the analysis, which is a disclosure we can live with. 🐕

The largest single study comes from Sweden. Mubanga and colleagues follow 3,432,153 adults through national registers for up to 12 years. Dog owners in single-person households have a hazard ratio for death of 0.67, against 0.89 in multi-person households, and cardiovascular death ratios of 0.64 and 0.85. Owners of hunting breeds have the lowest cardiovascular risk. Here is the catch. A separate analysis in the Swedish Twin Register, with 34,202 participants and richer lifestyle data, could not replicate the lower risk of cardiovascular disease or death, though it found no sign of confounding by disability, comorbidities or lifestyle. 🧠

The numbers to keep in your head:

• 24% lower all-cause mortality in the 2019 meta-analysis (10 observational studies, unadjusted)

• 33% lower mortality for dog owners living alone in Sweden (HR 0.67), against 11% in shared households (HR 0.89)

• Hunting breeds show the lowest cardiovascular risk in the Swedish data

• No replication in the smaller Twin Register subset

The fine print that shrinks the number

Dog owners are not a random sample of humanity, and that is the whole problem. A revised meta-analysis by Bauman and colleagues recalculates adjusted hazard ratios from the six population studies in the original analysis. A Psychology Today summary reports that the association is no longer significant once demographic and socioeconomic differences enter the model. A 2022 review in Current Hypertension Reports concludes that it is not possible to say conclusively that owning pets lowers all-cause mortality, though it may lower cardiovascular death. 🔬

Selection can also run the other way. In a Japanese cross-sectional survey of 9,875 older adults, socially isolated people had lower odds of owning a dog (OR 0.70). If lonely or frail people are less likely to keep dogs, dog owners look healthier by construction. That is textbook confounding.

The best recent attempt to deal with this is a 2024 PLOS One study that uses propensity score matching on 15,735 Australians, linked to the National Death Index through 2022. Dog owners have an odds ratio for death of 0.77 (95% CI 0.59 to 0.99) compared with non-owners. That interval brushes 1.0, and only 377 people (2.4%) died during four years of follow-up. Movement explains less than you would guess: physical activity accounts for about 7% of the total effect.

The American Heart Association’s 2013 scientific statement lands where we do. It says dog ownership is probably associated with lower cardiovascular risk and may have some causal role, but also says adopting a pet should not be done mainly to reduce that risk. 💊

How much to trust each number:

• Unadjusted pooled result (RR 0.76): treat it as an upper bound, because confounding likely inflates it

• Adjusted, matched result (OR 0.77): suggestive, but four years and 377 deaths is thin

• Swedish Twin Register: no replication, which we take seriously

• Randomized trials: we found none that assign adults to get a pet and then count deaths

How a pet might get under your skin

Start with stress, because the mechanism is where this gets interesting. In our piece on how loneliness ages you faster than smoking, we cover how the perception of being isolated activates the hypothalamic-pituitary-adrenal axis, the same stress system that kicks in when you are frightened. If a pet dampens that response, it could plausibly matter over decades. 🧬 There is lab support: a 2014 stress-test experiment, cited in a 2025 SHARE analysis, found that the presence of a dog attenuated cortisol and heart rate compared with human friends.

Loneliness is the second path. In a cross-sectional study of 830 older primary care patients, pet owners were 36% less likely to report loneliness (adjusted OR 0.64, 95% CI 0.41 to 0.98). Cross-sectional means we cannot tell which came first. The same logic runs through human relationships, which we cover in our look at how your social circle adds or subtracts years. 🧠

Then there is the body itself. The AHA statement lists increased physical activity, favorable lipid profiles, lower systemic blood pressure, improved autonomic tone and diminished sympathetic responses to stress among the reported effects. A later review adds that the evidence on dogs and recreational activity was not consistent.

Four pathways researchers point to:

• Stress buffering: lower cortisol and heart-rate responses when a dog is present (lab data)

• Loneliness relief: pet owners report less of it (cross-sectional, so direction unclear)

• Movement: real, but only about 7% of the mortality link in the Australian cohort

• Autonomic and blood pressure effects: listed by the AHA, with mixed consistency

When did a pet last get you out the door on a day you did not want to go? Keep that in mind for the next section.

Which pets do it best

Dogs have the strongest and broadest evidence, from mortality to cardiovascular outcomes. Cats are harder to place. In the Australian cohort, ownership of cats, birds, fish and others showed no clear association with mortality, despite owners having similar demographics to dog owners. Cognition tells a different story. The SHARE analysis follows adults 50 and older for 18 years across eight waves, with a main sample of 16,582 people. Dog and cat ownership go with slower cognitive decline, while bird and fish ownership do not. The authors declare no competing interests and note the findings are correlational. 🐈

The species subsamples are uneven: 1,886 dog owners and 1,778 cat owners, against only 447 bird owners and 266 fish owners. So “no association” for birds and fish is closer to “unknown” than “proven useless.” Two other cohorts point the same direction for cats and dogs. In the Baltimore Longitudinal Study of Aging, cognitive function deteriorates more slowly in pet owners, and cat owners show slower decline in recall and naming tasks. Among dog owners, walkers decline more slowly than non-walkers.

Living alone changes the picture. In 7,945 adults from the English Longitudinal Study of Ageing, mean age 66.3, pet owners who lived alone had slower declines in verbal cognition, memory and fluency, while the protective effect was not observed in those living with others. Sweden shows the same pattern for mortality. 🔬

A rough ranking, with error bars:

• Dogs: the deepest evidence for mortality, cardiovascular outcomes and cognition

• Cats: a cognitive signal in two cohorts, no mortality signal in a four-year study

• Birds and fish: no clear association, but small samples mean we simply do not know

• People who live alone: the benefit concentrates here in both Swedish and English data

How to use this without adopting for the wrong reasons

The AHA is right that nobody should get a pet as a medical intervention. Animals need daily care, and a bored dog helps no one. We think the better reading is that the daily routine a pet forces on you may carry much of the benefit. The Swedish finding that hunting breeds do best probably reflects activity, though the study does not prove it. 🧠

Dogs are also a longevity story from the other side. In our reporting on longevity startups, Loyal’s lead drug LOY-002 targets excess IGF-1 in senior dogs, and the FDA’s Center for Veterinary Medicine has accepted the safety and efficacy sections of its conditional approval application. The company’s STAY study enrolled 1,300 dogs across 70 clinics. Developments like this one don’t happen in isolation — and LongevityHub Pro is built to show you the full picture of companies, trials, and funding that surrounds them. 🧬

Before you adopt anything:

• Pick the species whose daily routine you will actually keep, including walks, feeding and vet visits

• If you live alone, the evidence for benefit is strongest, so weigh a dog or cat seriously

• Match a dog’s energy to your own, since active breeds show the best cardiovascular numbers in Sweden

• If you already own a dog, walk it, because in the Baltimore cohort walkers show slower cognitive decline

This week, count how many minutes a day your pet gets you moving or calms you down. If you do not have a pet, what else in your week gives you a reason to leave the house and someone to be responsible for?

Protein is the nutrient vegetarians get lectured about most and calculate least. 🧬 We think that is backwards. The evidence for plant-forward protein is friendlier than the online shouting match suggests, but it comes with arithmetic, and the arithmetic changed this year.

Below, we cover where the new target comes from and why some longevity researchers push back on it before age 65. Then we look at what the muscle trials say about vegetarian and vegan diets, the per-meal mechanism that sets how much you need at each sitting, and one real day of food that gets there. A lot of this evidence comes from small, short trials, and we flag that as we go. 🔬 Quick gut check before you read on: could you name yesterday’s protein total within 20 grams?

The target moved, and the evidence behind it is thinner than the headline

The 2025-2030 Dietary Guidelines for Americans came out on January 7, 2026 and set a protein goal of 1.2 to 1.6 grams per kilogram of body weight per day. Harvard’s Nutrition Source puts that at 50 to 100 percent above the old minimum. That old figure, the 0.8 g/kg RDA, is a floor meant to prevent deficiency. Nobody designed it to keep muscle on a 70-year-old. 🔬

Here is the catch. The new range rests on a rapid systematic review of randomized trials focused on weight-management outcomes, and a Journal of Nutrition perspective says the guidelines give limited attention to protein’s links with cardiovascular disease, type 2 diabetes, kidney disease, cancer and bone disease. The American Society for Nutrition’s summary of that paper adds that more research is needed to see how the range applies to different groups. So we treat 1.2 to 1.6 as a reasonable planning range, not a law of biology. 🧬 Here is how it sits next to the other numbers floating around:

• 0.8 g/kg: the RDA, the deficiency floor

• 1.2 to 1.6 g/kg: the Guidelines range

• 0.68 to 0.79 g/kg: Valter Longo’s suggestion for people under 65, which we unpack in our breakdown of his eating advice

• 1.6 to 2 g/kg: the intake the muscle trials below use for people who lift

For a 70 kg adult (about 154 pounds), the Guidelines range works out to 84 to 112 grams a day. The RDA gives 56. Do you know where you land right now? Log three ordinary days before you change anything, because guessing is a poor tool here. 🧠

Does more protein cost you years before 65?

Longevity circles split on this question, and the split traces back to one paper. 🧬 A 2014 study in Cell Metabolism, led by Morgan Levine in Valter Longo’s group, combined dietary data from 6,381 US adults aged 50 and older in NHANES III with mouse and cell experiments. People aged 50 to 65 who reported high protein intake had 75% higher overall mortality and four times the risk of cancer death over the next 18 years. Those links weakened or vanished when the protein came from plants, and in people over 65, high protein went with lower cancer and overall mortality.

The proposed mechanism runs through IGF-1. Protein restriction reduces growth hormone receptor and IGF-1 activity, and mice and humans with deficiencies in that pathway show major reductions in age-related disease. Critics are not convinced. An expert quoted by the Science Media Centre notes that the survey follow-up does not adjust for confounders such as socioeconomic status, smoking and obesity, and that much of the supporting work comes from mice.

A far larger dataset points the same way on protein source. The 2020 BMJ meta-analysis pools 32 prospective cohort studies with 715,128 participants followed for 3.5 to 32 years. Plant protein links to lower all-cause mortality (pooled effect 0.92) and lower cardiovascular mortality (0.88), and each extra 3% of energy from plant protein goes with about 5% lower risk of death. Both datasets are observational, so they show association, not proof. 🔬

What we take from this:

• Before 65, the right amount stays unsettled, and the strongest low-protein case rests on observational data plus animal work.

• Source shows up in both datasets: plant-derived protein looks better, in association only.

• After 65, Levine’s own numbers flip toward more protein, and muscle loss becomes the bigger worry.

• Neither dataset is a randomized trial with lifespan as the endpoint.

We think a vegetarian who lifts and gets most protein from plants, dairy and eggs sits on the comfortable side of this argument. Eating too little probably carries more risk than landing mid-range. 💊 Which camp are you in, and does your age change the answer?

What the muscle trials say about a vegetarian plate

Start with the good news. In a 2021 trial in Sports Medicine, 19 habitual vegans and 19 omnivores, all young men, did 12 weeks of supervised training twice a week, with protein topped up to 1.6 g/kg using soy for the vegans and whey for the omnivores. Both groups gained similar muscle strength and size. DuPont donated the whey and soy supplements, an industry link worth knowing about. 🔬

A 2023 Journal of Nutrition trial asks the same question at roughly 2 g/kg. Twenty-two healthy young adults complete 10 weeks of high-volume resistance training, 12 on an omnivorous diet and 10 on a mostly non-animal diet, and the authors report similar muscle adaptations regardless of protein source. The vegan diet leans heavily on mycoprotein, and one coauthor is affiliated with Marlow Foods, the company behind Quorn. Small sample, disclosed conflict, so we read it as encouraging rather than final.

The older-adult data is thinner but interesting. In a 2025 crossover trial, 34 community-dwelling adults averaging 72 years old ate a controlled vegan diet and a controlled omnivorous diet (60% animal protein), each for 10 days in random order. The authors conclude the vegan diet does not compromise daily muscle protein synthesis in physically active older adults. It lasts 10 days, and it excludes anyone who followed a vegetarian or vegan diet in the prior six months. 🧠

Then the pooled view. A 2025 meta-analysis in Nutrition Reviews pools 30 randomized trials on muscle mass and finds slightly lower muscle mass with plant protein than animal protein (standardized mean difference -0.20). The gap is not significant in adults 60 and older (-0.05). The detail vegetarians should care about: soy and milk protein do not differ across 17 trials, while animal protein beats non-soy plant proteins such as rice, chia, oat and potato in five trials. Strength and physical performance do not differ, and no trial examines sarcopenia as an outcome.

How we weigh all of it:

• Solid enough to act on: with matched protein and lifting, plant-heavy diets build muscle in young adults over 10 to 12 weeks.

• Promising: one 10-day crossover in 34 older adults finds equal daily muscle protein synthesis on a varied vegan diet.

• Thin: we find no long-term trial in older vegetarians that tracks muscle mass over months.

• Watch out: single-source rice, chia, oat or potato protein trails animal protein in the pooled data, so soy, dairy and eggs are your friends.

Why the per-meal number matters as muscle ages

Total daily protein is half the story. The other half is how you split it. When you eat protein, blood amino acids rise, and leucine helps switch on mTOR signaling in muscle, the machinery that starts building. Older adults show a meal threshold for leucine to trigger that signal, a state usually called anabolic resistance. 🧬

The cleanest dose data comes from Moore and colleagues in the Journals of Gerontology. They retrospectively analyze lab data from healthy older men (about 71) and younger men (about 22) who ate 0 to 40 g of high-quality protein in one bolus. Muscle protein synthesis plateaus at about 0.40 g/kg per meal in the older men and 0.24 g/kg in the younger men. For a 70 kg person, that is roughly 28 grams versus 17 grams. Note the limits: men only, a retrospective analysis, and not vegetarians. 🔬

Here is where plant-heavy eaters need to pay attention. Plant proteins generally contain less leucine per gram than whey, so a plant-heavy meal probably needs a bigger portion to send the same signal. Some 2024 reviews also argue that leucine levels predict the muscle protein synthesis response less reliably than long assumed, so we treat the threshold as a planning tool, not a cliff edge.

We cover the same mechanism for midlife women in our perimenopause checklist, which notes that protein supplementation only improves strength and lean mass when paired with resistance training. Timing is the other practical lever. A post hoc analysis of four randomized trials in 498 adults aged 55 and older links more protein at breakfast and lunch to a higher total daily intake, and intake at those meals is often low. Anyone who starts the day with toast and jam can see how that goes. 💊

Turning the mechanism into rules:

• Aim near 0.4 g/kg per meal once you pass 65, about 28 g at 70 kg. We would round up a little for plant-heavy meals.

• Anchor meals on dairy, eggs or soy, which usually sit at the leucine-dense end of a vegetarian menu.

• Put real protein at breakfast and lunch, not only at dinner.

• Lift regularly, because protein without training does little.

A 100 gram vegetarian day from ordinary food

Here is one day for a 70 kg adult that lands near 100 grams, about 1.4 g/kg and the middle of the Guidelines range. The figures below are approximate, based on USDA data for a cup of plain nonfat Greek yogurt or low-fat cottage cheese (25 g each), a cup of cooked lentils (16 g), one large egg (6 g) and a cup of soy milk (9 g), plus about 17 g per 100 g for firm tofu. 🧬

• Breakfast, about 30 g: 1 cup plain nonfat Greek yogurt plus a small handful of nuts

• Lunch, about 28 g: 1 cup cooked lentils and 2 eggs

• Afternoon, about 9 g: 1 cup unsweetened soy milk

• Dinner, about 34 g: 200 g of firm tofu with vegetables

• Swap: 1 cup low-fat cottage cheese for the yogurt, same 25 g

Check your own portions against USDA FoodData Central, because firmness and brand shift tofu and yogurt totals. If you like plate-based planning, our longevity plate template puts one quarter of the plate on legumes or whole grains, with fermented dairy or a soft-boiled egg as the optional protein, which fits neatly beside the anchors above.

Dairy and eggs do real work here. A Dutch simulation of 607 older adults finds that swapping animal foods for vegetarian ones cuts utilizable protein by about 5 percent, while in the vegan scenario 83.3% fall below the estimated average requirement. That is modeling, not measurement, but it matches what the trials suggest about protein quality. 🔬

The gap that bugs us most is older vegetarians. A registered trial, NCT06628349, compares plant-based and whey protein in older adults with and without sarcopenia, lists an estimated enrollment of 100 and a completion date of December 2026, and excludes people on vegetarian or vegan diets. That probably tells you how little vegetarian-specific data exists. If you’re following this area of longevity science professionally, LongevityHub Pro gives you the structured intelligence platform to go deeper than any single article can. 🧠

Tomorrow, write down every protein food you eat, use the USDA numbers, and check whether breakfast clears 25 grams. Which meal in your day is the weak link, and what would you swap in first?

We track VO2 max. We track HRV. We obsess over ApoB. Almost nobody tracks the one skeletal metric that quietly predicts whether a bad fall in your 70s turns into a bruise or a death sentence. 🦴 Bone density doesn’t trend on wellness podcasts because it doesn’t feel urgent, no dramatic before-and-after, no daily biofeedback, just a slow, invisible drawdown that shows up on an imaging report you probably haven’t had done. That silence is the problem. Osteoporosis has no symptoms until the moment it has a very serious one, and by then the numbers get grim fast.

The disease with no symptoms until it’s a hospital bed

Bone isn’t static scaffolding. It’s constantly being broken down by cells called osteoclasts and rebuilt by cells called osteoblasts, a churn that stays roughly balanced through your twenties. 🔬 Peak bone mass is generally reached by your mid-thirties. After that, the demolition crew starts slightly outpacing the construction crew, and the gap widens with age, and sharply during the menopause transition, when we’ve previously reported women can lose 5% to 10% of bone mineral density in a few short years. 📉

Doctors measure this with a dual-energy X-ray absorptiometry scan, or DEXA, which produces a T-score comparing your bone density to that of a healthy young adult. 🦴 A T-score of -1.0 to -2.5 means osteopenia, the precursor stage. Anything at -2.5 or below is osteoporosis. A few numbers worth sitting with:

• Roughly one in two women and one in four men over 50 will experience a fragility fracture in their remaining lifetime

• Osteoporotic fractures cause an estimated 432,000 U.S. hospital admissions and 180,000 nursing home admissions annually

• The disease is sometimes called the “silent epidemic” in clinical literature, precisely because it produces zero symptoms until a bone actually breaks

• Hip, spine, and wrist fractures are the three most common sites, and hip fractures carry by far the worst outlook

Here’s a question worth asking yourself honestly: do you actually know your T-score, or are you assuming your bones are fine because nothing hurts yet?

The mortality numbers hiding behind a hip fracture

This is where “silent” stops sounding harmless. A 2026 meta-analysis pooling 28 U.S. studies and more than 835,000 patients found one-year mortality after hip fracture averaged 21.8%, ranging as high as 54.4% depending on the population studied. 💀 A separate large retrospective cohort using the TriNetX health records network, tracking older adults with a first-time long bone fracture, found hip fractures carried a one-year mortality rate of 27.9%, a relative risk of 4.86 compared with age-matched patients who hadn’t fractured anything. That’s not a modest bump. That’s nearly five times the baseline risk of dying within a year. ⚠️

The Osteoporotic Fractures in Men (MrOS) study adds a subtler, arguably more useful data point: you don’t need to break a bone to be at elevated risk. Researchers tracked femoral neck bone density in 4,400 older men over roughly eight years and found that men with accelerated bone loss, defined by DEXA trend rather than a single reading, had a 44% higher risk of all-cause mortality than men whose bone density held steady, even without a fracture ever occurring (hazard ratio 1.44, 95% CI 1.23 to 1.68). A parallel NHANES cohort study of nearly 3,000 postmenopausal women found the same pattern: mortality rose significantly once femoral bone density crossed the osteoporotic threshold. 🔬 A quick summary of what these four studies actually found:

• 28-study meta-analysis, 835,226 patients: 21.8% average one-year mortality after hip fracture

• TriNetX cohort: 27.9% one-year mortality, nearly five times the risk of matched non-fracture controls

• MrOS study, 4,400 men, 8-year follow-up: 44% higher mortality with accelerated bone loss, no fracture required

• NHANES cohort, nearly 3,000 postmenopausal women: mortality rose once bone density crossed the osteoporotic threshold

We should be honest about what these numbers do and don’t show. All four are observational studies in humans, not randomized trials, so bone loss is traveling alongside frailty, comorbidity, and reduced mobility rather than acting entirely alone as a cause of death. But the dose-response relationship, more bone loss tracking with more risk, and the consistency across independent cohorts of men and women, is exactly the pattern epidemiologists take seriously rather than dismiss.

Screening finally caught up, mostly

For a long time, the honest answer to “when should I get a bone scan” was murky. That changed in January 2025, when the U.S. Preventive Services Task Force issued an updated recommendation: all women 65 and older should be screened (a B-grade recommendation), and postmenopausal women younger than 65 with elevated fracture risk should be screened using a DEXA scan rather than a risk-assessment questionnaire alone, a meaningful upgrade from the 2018 guidance. 📋 Task Force member Dr. Esa Davis put the rationale plainly: too often, the first sign of osteoporosis is a broken bone, and screening exists to get ahead of that.

Men got left out, and that gap deserves more attention than it gets. 🧬 The USPSTF issued an “I statement” for men, meaning the evidence is currently insufficient to weigh benefits against harms, not that men are at low risk. In fact, research summarized by clinical reviewers notes men are more likely to die following an osteoporosis-related fracture than women are, even though they’re diagnosed less often and screened even less. If you’re a man over 65 with risk factors, that guideline gap is a conversation to start yourself rather than wait for a form letter from your doctor’s office. ⚠️

A few practical screening notes:

• A T-score of -2.5 or lower confirms osteoporosis; -1.0 to -2.5 is osteopenia

• Risk factors that justify earlier screening include low body weight, smoking, a personal or family history of fracture, rheumatoid arthritis, and long-term steroid use

• The FRAX tool estimates your 10-year fracture probability and is worth asking your doctor to run alongside or before a scan

• One scan is a snapshot. A second scan two years later, showing the trend, is where the real signal lives

What actually moves the needle

Here’s the genuinely good news: bone responds to mechanical stress at any age, and the evidence for exercise is stronger than most people assume. The LIFTMOR trial, published in the Journal of Bone and Mineral Research, put postmenopausal women with low bone mass, including diagnosed osteoporosis, through eight months of twice-weekly high-intensity resistance and impact training at more than 85% of their one-rep max. Lumbar spine bone density rose 2.9% in that group while a low-intensity comparison group lost 1.2%, adherence exceeded 90%, and a follow-up safety analysis found no vertebral fractures from the loading. 💪 A broader 2025 meta-analysis of 17 randomized trials and 690 postmenopausal women confirmed the pattern at the lumbar spine and femoral neck more generally, meaning LIFTMOR wasn’t a fluke.

For higher-risk cases, the drug landscape has genuinely changed too. 💊 Romosozumab (brand name Evenity), approved in 2019, works differently from older bisphosphonates: it’s an anabolic agent that builds new bone rather than only slowing its breakdown. Worth flagging honestly, since this is industry-funded trial data from manufacturer Amgen: the ARCH trial found a small but real imbalance in cardiovascular events, 50 in the romosozumab group versus 38 on alendronate, which led the FDA to require a boxed warning and limit the drug to a 12-month course, followed by an anti-resorptive medication. It’s not a first-line option for everyone, and your cardiovascular history genuinely matters in that conversation. 🩺 For anyone tracking how quickly the osteoporosis treatment landscape is shifting between anabolics, bisphosphonates, and denosumab, LongevityHub Pro has you covered on the trial data and regulatory detail a single article can’t hold.

Nutrition plays a supporting role rather than a starring one. Vitamin D drives calcium absorption in the gut, and pairing it with vitamin K2 helps direct that calcium toward bone rather than arterial walls, a mechanism we’ve covered in more depth in our piece on the supplements doctors over 50 actually take. Supplementing without a documented deficiency shows limited additional benefit, so testing your levels first beats guessing. A rough hierarchy of what the evidence actually supports, strongest first:

• Loaded resistance and impact training, the single best-documented lever, per LIFTMOR and the broader meta-analysis above

• Correcting a genuine vitamin D or calcium deficiency, confirmed by blood work rather than assumed

• Anabolic or anti-resorptive medication for those already diagnosed with osteoporosis or at high fracture risk

• General weight-bearing activity like walking, which helps but produces a smaller effect than true resistance loading

What to actually do about it

None of this requires waiting for a crisis. 📋 A short, concrete list:

• If you’re a woman 65 or older, ask your doctor for a DEXA scan now if you haven’t had one; it’s covered under current USPSTF guidance

• If you’re a postmenopausal woman under 65, or a man over 65, ask your doctor to run a FRAX score even if a scan isn’t automatically offered

• Start or maintain resistance training that includes real loading, not just light bands, twice weekly if your bones can tolerate it 💪

• Get vitamin D and calcium levels tested rather than supplementing blindly

• If you’ve already had a scan, ask for the actual T-score and file it somewhere you’ll find again in two years, since the trend matters more than the single number

We covered the earliest signs of this decline in our perimenopause longevity checklist, and the safest way to train around it in our injury-proof guide to strength training after 50, so the tools already exist. 🦴 The only missing piece, for most people, is simply asking for the number. So here’s the honest question: when was the last time you actually saw your own T-score, and what would it take to find out this month instead of after something breaks?

Snoring gets treated like a punchline. Sleep apnea, the condition often hiding underneath it, does not deserve one. Obstructive sleep apnea (OSA) affects an estimated 1 billion adults worldwide, and the American Academy of Sleep Medicine puts the untreated U.S. figure at roughly 30 million people, a large share of whom have no idea they have it. 😴 That gap between how common this is and how seriously we take it is the actual story here. We’re not talking about morning grogginess. We’re talking about a condition with measurable effects on how long you live and how fast your body ages while you’re still alive to notice it.

What snoring is actually hiding

Simple snoring is just noisy airflow. OSA is your airway physically collapsing, dozens of times an hour, cutting off breathing and dropping your blood oxygen before your brain jolts you awake just enough to reopen it. 🌬️ You rarely remember these arousals. Your body remembers every one. Doctors grade severity using the apnea-hypopnea index (AHI), which counts these events per hour of sleep: mild sits around five to fourteen, moderate runs fifteen to twenty-nine, and severe means thirty or more. That’s someone stopping breathing roughly once every two minutes, all night, for years. 😮‍💨

The mechanism that does the damage is called intermittent hypoxia, repeated cycles of oxygen dropping and then rebounding. That whiplash triggers oxidative stress and systemic inflammation, the same two pathways implicated in most chronic disease. A few things worth knowing about who’s affected:

• Risk climbs sharply with age, obesity, and after menopause in women

• Roughly 80% of people with OSA are undiagnosed, according to industry estimates cited by device makers and sleep clinics 🧬

• Men are diagnosed more often, but that’s partly a detection bias. Women’s OSA symptoms present differently and get missed

• A family history of loud snoring or witnessed breathing pauses is a real risk signal, not just an anecdote

Here’s a question worth sitting with: has a partner or roommate ever told you that you stop breathing at night? That offhand comment is actually clinical data, and it’s usually the first sign anyone gets.

The mortality math researchers actually have

This is where “just snoring” falls apart. The Wisconsin Sleep Cohort, an 18-year longitudinal study in humans published in the journal Sleep, found that people with severe OSA had roughly three times the risk of dying from any cause compared with people without it, an adjusted hazard ratio of 3.2 after controlling for age, sex, and body mass index. 📉 When researchers removed the participants who reported using CPAP therapy regularly, that hazard ratio climbed to 4.3. Treatment, in other words, was doing real work in that gap.

A separate population cohort study measured something more tangible than a hazard ratio: actual years of life. Using a three-state survival model starting at age 40, researchers found that sleep-related breathing disorders were associated with losing 7.32 years of cardiovascular-disease-free life expectancy in women (95% CI, 5.33 to 10.34) and 6.73 years in men (95% CI, 5.31 to 8.48), compared with people without the condition. 🫀 That’s not a rounding error. That’s most of a decade of healthy years, gone quietly, one disrupted night at a time.

We should flag the honest limitation here: both of these are observational studies in humans, not randomized trials, so they show strong association rather than airtight proof that OSA alone, independent of the obesity and hypertension that often travel with it, causes every one of those lost years. 🔬 But the adjustment for BMI and other risk factors in both studies, and the dose-response pattern between severity and risk, make this a signal worth taking seriously rather than dismissing as confounding.

Your cells are aging faster than your birthday count

Longevity science cares about biological age, not just the number on your birthday cake, and OSA has a growing paper trail here too. 🔬 A 2025 bidirectional Mendelian randomization study in Frontiers in Genetics, using genetic data from 217,955 people with OSA and 472,174 people with telomere length measurements, found a statistically significant negative causal relationship between genetically predicted OSA and telomere length (odds ratio 0.964, 95% CI 0.939 to 0.980), with no evidence that short telomeres cause OSA in reverse. That directionality matters. It’s genetic evidence, not just correlation, that the breathing disorder is aging your cells rather than the other way around.

Smaller human cohort studies back this up with a more direct measurement. A 2025 study in Scientific Reports recruited 99 sleep clinic patients and found telomere length was significantly shorter in those with more severe OSA, even after adjusting for age, sex, and BMI. 🧬 Separately, an NHANES-based analysis published in Clinical Epigenetics linked OSA symptoms to acceleration on two established biological-age clocks, KDM-Age and PhenoAge, in a large observational human sample. None of this proves reversal is impossible, just that the baseline trajectory bends the wrong way.

One caveat we owe you, because LongevityHub doesn’t blur this line: a widely cited 2026 study from Marshall University and the University of Missouri, led by David Gozal and Mohammad Badran and published in npj Aging, found that intermittent hypoxia mimicking OSA drove premature cardiovascular aging and higher mortality, including stiffer blood vessels and impaired heart function. That study was conducted in mice, not people. 🐭 It’s genuinely useful for explaining mechanism, but it’s not evidence about your personal lifespan the way the human cohort data above is. Keep those two categories separate in your head.

Treatment finally caught up, a little

The good news, and there is real good news, is that treatment changes these numbers. 💊 A large meta-analysis in the European Respiratory Journal found consistent CPAP use was associated with a 62% reduction in cardiovascular mortality among people with severe OSA, compared with those who abandoned or refused treatment. The word “consistent” is doing real work in that sentence. Benefit tracks with hours worn per night, and researchers generally consider four hours nightly the floor for any measurable effect, with seven or more hours delivering the strongest results.

December 2024 brought the first real alternative to the mask. 🩺 The FDA approved tirzepatide (brand name Zepbound) as the first medication for moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA trials, randomized, double-blind, placebo-controlled studies in 469 people, which showed the drug cut apnea-hypopnea events by 25 to 29 per hour compared with placebo. It works by driving weight loss, one of the biggest modifiable drivers of airway collapse in the first place, rather than mechanically propping the airway open. If you’re following how quickly the treatment landscape for a single sleep disorder is shifting right now, LongevityHub Pro gives you the structured intelligence platform to go deeper than any single article can, since Zepbound, CPAP, and the wearable screening tools below are really three separate stories moving at once.

There’s even early, cautious evidence the cellular damage might be partly reversible. 🔬 A small six-month, sham-controlled pilot trial in men with moderate-to-severe OSA tracked telomere length before and after CPAP treatment. It’s a pilot study with just 46 participants split unevenly between the CPAP and sham arms, so treat it as a promising lead rather than a settled fact, but it’s the right kind of study to be running.

How you’d actually find out

None of this helps if you don’t know your own status, and this is genuinely one of the fastest-moving corners of consumer health tech right now. ⌚ Apple’s Sleep Apnea Notification feature received FDA clearance in September 2024 after a trial of 1,448 people, with a sensitivity of 66.3% and specificity of 98.5% for moderate-to-severe cases, meaning it misses a real chunk of cases but rarely raises a false alarm. 📊 Samsung cleared a similar feature on the Galaxy Watch in February 2024, and by mid-2026 had extended it to the Galaxy Ring, the first FDA-cleared smart ring in this category. None of these devices diagnose anything. They flag a probability worth acting on. 🔍 A quick, practical checklist if you suspect this applies to you:

• Ask a partner, or record yourself, to check for loud snoring, gasping, or witnessed breathing pauses

• Note morning headaches, dry mouth, or waking up feeling like you never slept at all

• If you wear a smartwatch with the feature enabled, check whether it’s flagged elevated breathing disturbances

• Ask your doctor about a home sleep apnea test rather than assuming you need an overnight lab study

• If your resting heart rate or HRV has been trending in the wrong direction lately, treat that alongside the longevity biomarkers worth tracking at home, since disrupted breathing shows up there too

We’ve written before about how poor sleep quietly ages the brain and what a consistent sleep schedule does for mortality risk generally, and OSA is the sharpest version of that same story: the damage happens while you’re unconscious, which is exactly why it goes undiagnosed for years. So here’s the honest next step, not a vague one: when was the last time anyone, a partner, a doctor, a watch on your wrist, actually looked at how you breathe while you sleep?

Here’s a fact that doesn’t get said out loud enough: heart disease is the leading cause of death in women, and the years surrounding menopause are when the trajectory toward it actually gets set. Not at 65. Not “eventually.” Now, in the stretch of roughly five years bracketing your final period. 🫀 We’ve written before about the perimenopause longevity checklist and the many systems that shift during this decade. This time we’re going deep on one system in particular, because 2025 and 2026 delivered a stack of new evidence, plus a genuinely stunning regulatory reversal, that changes what “doing something about it” actually looks like.

Why your arteries notice menopause before you do

The idea that heart risk “starts” at menopause is outdated. It starts earlier, and the Study of Women’s Health Across the Nation (SWAN) has the receipts. In one analysis of 249 women aged 42 to 52 at the Pittsburgh site, researchers used repeated ultrasounds to track the carotid artery through the menopause transition. During late perimenopause, defined as three or more months without a period, artery wall thickness increased by an average of 0.017 millimeters a year and diameter by 0.024 millimeters a year, both significantly faster than during the premenopausal years. Lead author Samar El Khoudary described late perimenopause as a stage of vascular remodeling, when arteries become measurably more vulnerable regardless of a woman’s age or ethnicity.

That’s not the only marker moving. A separate SWAN Heart ancillary study followed 411 women for an average of 2.3 years and found that those going through the transition had faster increases in aortic pulse wave velocity, a measure of arterial stiffness, than women who stayed premenopausal or postmenopausal throughout. And a third SWAN analysis of 471 women found a steep rise in LDL cholesterol particles clustered tightly around the final menstrual period, with higher LDL particle counts and apolipoprotein B tracking with more coronary calcium and thicker carotid walls later on. 🔬

The mechanism isn’t mysterious. Estrogen keeps arteries flexible, helps regulate cholesterol clearance, and calms inflammation. When it falls, all three jobs go undone at once. Quick recap of what tends to move during this window:

• LDL cholesterol and apolipoprotein B, often up 10 to 15 percent

• Carotid artery thickness and diameter

• Aortic pulse wave velocity (arterial stiffness)

• Visceral, abdominal fat distribution

• Blood pressure, in some but not all cohorts

Worth sitting with: none of this requires you to feel anything. These are silent, measurable shifts that show up on imaging and blood work well before symptoms would ever prompt a visit to a cardiologist.

The five years that do the most damage

So why five years specifically, and not ten, or twenty? Because that’s roughly where the data clusters. Longitudinal research on lipid changes shows the sharpest movement in LDL-C, apolipoprotein B, and triglycerides happening in the two years surrounding the final menstrual period, with some cohorts showing the effect stretching out to six years afterward. A separate retrospective study compared 90 postmenopausal women scanned within their first five years of menopause against 90 age- and BMI-matched women scanned during years five through ten. The later group had a significantly higher android-to-gynoid fat ratio (a marker of the more dangerous, apple-shaped fat distribution) and a modestly but statistically significantly higher ten-year cardiovascular risk score, 3.74 percent versus 3.28 percent. Small numbers, but a real, measurable divergence that keeps building with time since your last period.

Context matters here, and how menopause arrives changes the math considerably. A large cohort study out of Northwestern Medicine found that women who go through natural menopause before age 40 face roughly a 40 percent higher lifetime risk of coronary heart disease compared with women who reach menopause later, a gap that held even after adjusting for smoking, obesity, hypertension, and diabetes. Cardiologist Amy Freaney, who worked on the study, put it plainly: women with premature menopause need to treat it as an early flag, not a footnote, and bring it up with their doctor directly rather than waiting to be asked. 💊

A few things to flag honestly, because LongevityHub doesn’t do vague optimism: this is mostly observational data, meaning it shows strong association, not airtight proof that menopause itself, independent of aging, causes every one of these changes. And the “five years” framing is a synthesis of several overlapping windows (two years, six years, ten years) rather than one single trial with a five-year cutoff stamped on it. What’s consistent across all of them is the direction: the changes are real, they’re concentrated in the years right around the transition, and they compound the longer they go unaddressed. Have you had your cholesterol or ApoB checked since your cycle started changing? If the honest answer is “not recently,” you’re not alone, and it’s worth fixing this year rather than next.

The FDA just rewrote the rulebook, and not everyone is cheering

This is the part that makes late 2025 a genuinely different moment for this topic. On November 10, 2025, the FDA announced it would remove the black box warnings, the highest-level safety label the agency uses, from hormone therapy products containing estrogen, striking references to cardiovascular disease, breast cancer, and probable dementia risk. The agency is keeping the boxed warning for endometrial cancer on systemic estrogen-only products. Labels are expected to be rewritten within six months to include age-specific guidance reflecting what’s become known as the timing hypothesis: that starting hormone therapy within about ten years of menopause onset, or before age 60, is associated with a more favorable cardiovascular profile, while starting it later is linked to higher risk.

The evidence behind this isn’t new so much as re-read. Subgroup analyses of the original Women’s Health Initiative trial found that women who started hormone therapy within that early window showed trends toward reduced coronary heart disease, hazard ratios of 0.76 for estrogen plus progestin and 0.59 for estrogen alone, though the first of those didn’t reach statistical significance. The randomized ELITE trial added more direct mechanistic support, showing that estradiol slowed atherosclerosis progression in early postmenopausal women but not in those further out from menopause. LongevityHub Pro turns individual breakthroughs like this one into a searchable, connected picture of where the field is actually heading, which is genuinely useful once you start noticing how many separate strands, WHI subgroups, ELITE, KEEPS, DOPS, feed into a single label change.

Not everyone thinks the FDA got the process right. Adriane Fugh-Berman, a pharmacology professor at Georgetown, told NPR the panel that recommended the change felt like “theater, not scientific evaluation,” arguing the agency skipped its usual rigor. That’s a fair caution to hold alongside the excitement: an association found in decades-old subgroup analyses is not the same thing as a fresh, purpose-built randomized trial, and individual risk still depends heavily on your personal and family history of clots, hormone-sensitive cancers, and existing cardiovascular disease. 🧬

What to actually do in this window

None of this is an argument that everyone should start hormone therapy, and it’s not medical advice tailored to you specifically, it’s a case for taking the conversation seriously and having it with real numbers in hand rather than vague worry. A few concrete moves:

• Get a full lipid panel done, and ask specifically about apolipoprotein B rather than just LDL, since it’s a sharper predictor. We’ve broken down why ApoB matters more than standard cholesterol if you want the deeper explanation

• Know roughly how many years out from your final period you are. It’s the single number that changes the entire hormone therapy risk calculation

• Ask your doctor to run a formal ASCVD risk score, not just a gut check based on your age

• If cardio has fallen off since perimenopause symptoms started, Zone 2 training is one of the most evidence-backed, low-drama ways back in

• Bring your family history of premature menopause, early heart disease, and clotting disorders to the appointment. It changes the calculus more than almost anything else

This window closes quietly. Nobody sends a reminder when you’re two years past your last period versus seven. The women who come out the other side of this decade with the best numbers tend to be the ones who checked in on their heart proactively rather than waiting for a symptom to force the issue. So: when did you last actually look at your numbers, and are you willing to book that appointment this month instead of someday?

Walk into any high-end gym now and you’ll find both: a cedar box heated to 174°F and a steel tub chilled to 50°F, usually sitting a few feet apart like rival gladiators. The wellness world treats them as interchangeable, two flavors of the same “hormetic stress” sundae. They are not interchangeable. One has a genuine, decades-long human evidence trail tied to actual death rates. The other has a handful of small, short-term studies and an awful lot of enthusiasm.

We went looking for the actual data behind both, not the Instagram captions. Here’s what holds up, what doesn’t, and which one deserves the bigger chunk of your recovery routine. 🔬

The 20-year Finnish data that actually built the sauna case

Sauna research isn’t new, and it isn’t thin. The anchor study here, published in JAMA Internal Medicine in 2015, followed 2,315 middle-aged Finnish men for a median of 20.7 years as part of the Kuopio Ischaemic Heart Disease Risk Factor Study. Men who used a sauna four to seven times a week had a 40% lower risk of all-cause mortality and a 63% lower risk of sudden cardiac death compared to men who used one just once a week, and the effect scaled with frequency in a clean dose-response pattern. That’s not a fluke finding buried in a small sample. That’s nearly a thousand deaths tracked over two decades.

The same research group came back in 2016 with something even more interesting: frequent sauna use was associated with a 66% lower risk of dementia and a 65% lower risk of Alzheimer’s disease in that same cohort. 🧠 A 2018 follow-up extended the cardiovascular findings to include women, roughly half the 1,688-person sample, and found the protective association held for both sexes.

Now, the caveat, because we’d be lying to you otherwise:

• This is observational cohort data, not a randomized trial, so causation isn’t proven

• In Finland, sauna use is so culturally universal that the “low frequency” comparison group still used one weekly, not zero, which may understate the true effect size, or complicate it

• The mortality and dementia studies were conducted almost entirely in men, so generalizing to women needed that separate 2018 paper to even partially confirm

• Confounding is a real concern: people who sauna four to seven times a week probably also exercise more, drink less, and manage stress better

Mechanistically, sauna heat raises core temperature and heart rate similarly to moderate exercise, and it triggers heat shock proteins, molecular chaperones that help refold damaged proteins and support cellular repair. That’s a plausible biological story for why heat exposure tracks with better cardiovascular and brain outcomes, but plausible mechanism plus strong correlation still isn’t the same as a clinical trial.

Cold plunge’s evidence is thinner and a lot more of a mixed bag

Here’s where we have to be the “rigorous” half of Rigorous Optimist. A 2025 systematic review in PLOS One, led by researchers at the University of South Australia, pooled 11 studies covering nearly 3,200 people and found that cold-water immersion does reduce stress and modestly improve quality of life, but those effects faded fast. Stress reduction lasted about 12 hours. Quality-of-life improvements from repeated cold showers disappeared entirely after three months. One study in that review found people took 29% fewer sick days after regular cold showers, which is genuinely interesting, but a sleep-improvement finding in the same review was restricted to male participants only, so we can’t say it generalizes.

Here’s the part that should give you pause before you buy a $6,000 tub: the review found cold-water immersion significantly increases inflammation within the first hour after exposure. That’s the opposite of the “reduces inflammation” claim you’ll see on every cold plunge company’s homepage. The researchers explain it as an acute stress response, similar to how exercise causes temporary muscle damage before adaptation kicks in, but they also flag that people with existing heart disease, high blood pressure, or diabetes should talk to a doctor first, since that inflammatory spike isn’t necessarily benign for everyone. ⚠️

You’ll also see cold plunge blogs cite a famous mouse study claiming lower body temperature extends lifespan. Worth untangling that one directly: the 2006 Science paper from Scripps Research genetically engineered mice to run their core temperature 0.3 to 0.5°C cooler around the clock, and those mice lived up to 20% longer. That’s a real, influential finding, but it has almost nothing to do with jumping into a cold tub for three minutes. It’s a permanent internal thermoregulation change in mice, not a brief external cold shock in humans, and treating the two as equivalent is the kind of leap that makes us wince a little.

Actually, cold plunging right after a lift might backfire

If you’re pairing your workout with an ice bath because you think it speeds muscle repair, here’s a finding that deserves more attention than it gets. A controlled trial published in the Journal of Applied Physiology in 2019 put 16 men through seven weeks of resistance training, with half doing 15 minutes of cold water immersion after each session and half doing passive recovery. The cold group showed blunted muscle fiber hypertrophy and reduced activation of the mTOR pathway, the primary signaling cascade your body uses to build new muscle tissue. Strength gains were similar between groups, so your one-rep max probably won’t suffer, but if size is the goal, cold water right after lifting seems to work against you.

A broader meta-analysis of eight randomized trials and 116 participants, summarized by the research review site Examine, found the same pattern: post-lift cold water immersion reliably shrinks hypertrophy gains, even if the effect size is modest. 💪 This is a case where the recovery-industrial complex sold everyone the same protocol for two completely different goals, endurance recovery and muscle building, and they don’t actually point the same direction.

Practical fixes if you lift and plunge:

• Save cold immersion for cardio or endurance recovery days, not leg day

• If you must plunge after lifting, wait at least four to six hours to avoid blunting the anabolic signaling window

• Use active recovery (light movement, not ice) if hypertrophy is your primary goal

• Reserve the tub for stress relief and alertness on its own schedule

Have you been icing your gains without realizing it? It’s a genuinely common mistake, even among people who train seriously.

So which one should you actually prioritize

If we’re being honest about the weight of evidence, sauna wins this comparison by a wide margin. It has multiple decades of large cohort data tied to hard outcomes, death and dementia diagnosis, not just mood surveys. Cold plunge has smaller, shorter studies, mostly measuring subjective wellbeing, with effects that fade within months and a genuinely confusing inflammation signal.

That gap might close. In October 2025, the cold plunge company Plunge announced a research partnership with the Medical University of South Carolina to formally study its cold and heat systems, with the university’s Dr. Mark Rosenberg leading the work. That’s worth watching, and also worth reading with your skeptic hat on, since the company funding the equipment has an obvious commercial interest in favorable results. Developments like this one don’t happen in isolation, and LongevityHub Pro is built to show you the full picture of companies, trials, and funding that surrounds them. We’ll keep tracking what comes out of it.

None of this means skip the cold plunge entirely. The hormesis framework, where a controlled stressor triggers a beneficial adaptive response, is a real and well-documented phenomenon biologically, even if the cold-specific longevity data in humans isn’t there yet. Cold exposure genuinely does spike norepinephrine and dopamine and can sharpen alertness for hours. That’s a legitimate, if modest, benefit on its own terms.

Building a routine without the marketing hype

Given everything above, here’s how we’d actually weight a hot-cold routine if longevity is the real goal:

• Prioritize sauna sessions 4 to 7 times a week if your schedule and heart health allow it, aiming for roughly 15 to 20 minutes at a time

• Treat cold plunging as a mood and alertness tool, not a proven longevity lever, and use it a few times a week if you enjoy it

• Never go straight from a hot sauna into an ice bath if you have any cardiovascular risk factors, since the rapid vasoconstriction-vasodilation swing has been flagged as a strain on the heart

• Keep cold immersion away from strength training days, or at least several hours removed from your lifting session

• Talk to your doctor before starting either practice if you have heart disease, uncontrolled blood pressure, or are pregnant

We’d love to tell you cold plunging is the free, five-minute biohack that rivals decades of Finnish sauna data. It isn’t, at least not yet. What’s your actual routine look like right now, heavy on heat, heavy on cold, or are you doing both without much of a plan? Pick the one with the stronger evidence behind it and give it a real four-week trial before you decide the other one is worth the investment too.

About 1 in 5 workers worldwide clock in while the rest of the world sleeps. Nurses, pilots, factory workers, cops, baristas doing the 4 a.m. bake shift: all of them are running on a schedule their biology never evolved for. Your suprachiasmatic nucleus, the tiny cluster of brain cells that runs your internal clock, doesn’t care what your calendar app says. It wants light in the morning and darkness at night, full stop.

We’re not here to tell you to quit your job. We’re here because the chronobiology research on shift work has gotten a lot more specific in the last two years, and some of it is genuinely actionable. 🧬 Below is what the evidence actually supports, what’s still shaky, and what you can start doing tonight.

Why your body clock treats the night shift like an act of war

Here’s the mechanism, because it explains everything else in this piece. Your central clock releases melatonin in response to darkness and suppresses it with light exposure, and that single signal cascades into blood pressure, insulin sensitivity, immune function, and mood. When you work nights, you’re bathed in bright light exactly when your brain expects darkness, then you try to sleep during the hours your cortisol is climbing to wake you up. That’s circadian misalignment, and it’s not a minor inconvenience. 🔬

The health data on this is sobering, though not catastrophic. A 2025 dose-response meta-analysis found that night shift work raises the risk of total cardiovascular disease events by about 13% and total cardiovascular mortality by roughly 27%, with each additional five years of shift work adding measurably more risk. Separately, the World Health Organization’s cancer research arm classified night shift work as “probably carcinogenic to humans” in 2019, based on limited evidence in humans for breast, prostate, and colorectal cancers, sufficient evidence in animal studies, and strong mechanistic evidence involving immune suppression and chronic inflammation. That’s a Group 2A classification, the same tier as red meat, not the same tier as tobacco. Context matters here 😌.

What actually gets disrupted:

• Blood pressure and clotting factors, which worsen after simulated night work in lab studies

• Glucose tolerance and insulin sensitivity

• Melatonin’s antioxidant role in repairing everyday DNA damage

• Mood regulation, independent of how much sleep you actually get

• Immune signaling tied to inflammation

None of this means your health is doomed because you work nights. It means the timing of your habits matters more than it would for a 9-to-5 worker, and that’s actually good news, because timing is something you can control.

The meal-timing trick that outperformed everyone’s expectations

If you take away one thing from this article, make it this: when you eat might matter more than what you eat during a night shift. A 2025 randomized controlled trial in Nature Communications, led by Frank Scheer and Sarah Chellappa, randomized 20 healthy participants into simulated night work, with one group eating during both day and night (typical for shift workers) and the other eating only during daytime hours. After simulated night work, the nighttime-eating group showed a 25.7% drop in a key heart-rate variability marker, a 14.3% drop in another, a 5.5% rise in a stress-linked cardiac ratio, and a 23.9% increase in a blood-clotting risk factor, while blood pressure fell 6 to 8%. The daytime-only eaters showed none of these changes, despite having identical, mistimed sleep. That’s the striking part: sleep was still wrecked in both groups, and food timing alone moved the needle.

This isn’t a one-off finding. The same research group previously showed daytime-only eating prevented glucose intolerance and internal circadian misalignment in a smaller 2021 trial, and reduced depression- and anxiety-like mood shifts in a 2022 study. Three separate trials, same lab, same direction. That’s the kind of consistency that makes a “we” at LongevityHub sit up. 📈 Worth noting: these are small, tightly controlled lab studies (19 to 20 healthy young adults, not real shift workers eating real cafeteria food), so the researchers themselves say the next step is testing this in actual working night crews. Want to know how this fits into the broader longevity landscape — the companies, the competing trials, the money behind the science? LongevityHub Pro has that map.

Practical takeaways while we wait on real-world trials:

• If you work nights, try confining meals to daylight hours, even a small snack instead of a full meal at 3 a.m.

• A protein- and fiber-forward breakfast before your shift beats sugar-heavy vending machine food during it

• Avoid large meals in the two hours before your daytime sleep window

• Hydrate early in your shift, since dehydration compounds fatigue

Have you actually tried shifting your eating window to daylight hours, or does your job make that close to impossible? It’s worth experimenting with even on your next rotation.

Light is the steering wheel, not just scenery

Light is the single strongest cue your circadian system responds to, which makes it a genuinely useful lever. A 2026 meta-analysis in Scientific Reports pooled 16 studies and 311 participants exposed to at least 1,000 lux of light during simulated night shifts, and found that bright-light exposure improved overall cognitive performance, alertness, and attention or reaction time compared with dim-light controls. The catch: participants were mostly young (average age 24) and 78% male, and cumulative light exposure over time actually reduced the benefit, suggesting more light isn’t automatically better. Certainty of evidence was rated moderate at best. 🔦

An earlier 2022 meta-analysis of night-shift nurses found that blue-enriched white light, above 5,000 Kelvin specifically, was more effective at cutting sleepiness than standard white light. That’s a useful, specific detail if your workplace lets you choose bulb temperature.

How to actually use this:

• Seek bright, blue-enriched light in the first half of your shift to anchor alertness

• Wear blue-light-blocking glasses on your drive home, since morning sunlight is the exact signal that tells your brain to wake up, which is the last thing you want before daytime sleep

• Keep your bedroom genuinely dark: blackout curtains, not just dim ones

• Avoid bright screens for the hour before your daytime sleep window

None of this is exotic biohacking. It’s mostly about controlling a variable your body was already responding to whether you noticed or not.

Naps, melatonin, and the science of catching up on sleep you’ll never fully get back

Let’s talk about naps, because the research here is more specific than “just take a nap.” A Hiroshima University reanalysis of pilot studies on 16-hour night shifts compared no napping, a single 120-minute nap, and a split nap of 90 minutes followed later by 30 minutes, in 41 total participants. The single long nap delayed drowsiness until roughly 4 a.m., while the split nap pushed it back to around 6 a.m. A separate meta-analysis of 18 studies and 494 participants found the average effective nap length during night shifts was about 42 minutes. The lesson: when you nap and how you split it matters as much as whether you nap at all.

Now, melatonin supplements, where the evidence is genuinely mixed and worth being honest about. A 2025 randomized, placebo-controlled trial in Occupational and Environmental Medicine gave 40 night shift workers 3 mg of melatonin an hour before daytime sleep for four weeks, and found a borderline-significant 1.8-fold increase in a urinary marker of oxidative DNA repair capacity (p = 0.06), with no significant effect during the subsequent night shift itself. That’s promising, not proven. It’s a small trial, most participants worked in healthcare, and the researchers explicitly call for larger studies before anyone treats melatonin as a settled cancer-prevention strategy. Separately, other trials suggest melatonin can modestly shorten the time it takes to fall asleep and extend total sleep time in shift workers, but effects on next-day performance have been inconsistent.

Some ground rules if you’re considering it:

• Melatonin is sold as a supplement in the US, not regulated as a drug, so dose and purity vary by brand

• Timing matters: taken right before your intended daytime sleep, not randomly

• It interacts with some blood pressure medications and antidepressants, so check with a pharmacist

• It’s a sleep aid, not a proven substitute for consistent circadian habits

Building a rhythm you can actually sustain

The single most protective habit across the research, more than any supplement, is keeping a consistent sleep-wake window even on your days off. Constantly swinging between a night-shift schedule during the week and a normal schedule on weekends is its own form of chronic jet lag, and it undoes a lot of the good work above. 🧠 If you can, try “anchor sleep,” protecting at least a few core hours of overlap between your work-day and off-day sleep windows, instead of flipping entirely.

One more thing worth saying plainly: if sleep problems tied to your schedule last more than three months, that’s a recognized condition, shift work disorder, and it’s worth bringing up with a doctor or your workplace’s occupational health team rather than white-knuckling it indefinitely.

• Protect a consistent core sleep window, even on off days

• Eat on a daytime-aligned schedule when your shift allows it

• Front-load bright light early in your shift, block it on the commute home

• Split your napping strategy instead of relying on one long nap

• Talk to a professional if sleep issues persist past three months

So, what’s the one variable from this list you can actually control starting with your next shift: meal timing, light exposure, or your nap structure? Pick one and give it two weeks before judging whether it worked.

You finished the pills. The infection is gone, the fever broke, and you feel mostly like yourself again. Except maybe not entirely. Digestion feels off, energy is patchy, and you can’t quite explain why 🧬. That’s your gut microbiome, and it just went through something real.

Antibiotics are blunt instruments. They can’t tell the difference between the bacteria causing your sinus infection and the trillions of bacteria that quietly run your digestion, train your immune system, and manufacture compounds your brain and metabolism depend on. Kill the invaders, and a lot of the residents go down too. What we get asked most at LongevityHub isn’t whether antibiotics disrupt the gut, that part is settled. It’s what actually rebuilds it afterward, and what’s mostly wishful thinking sold in capsule form 💊. We went through the research so you don’t have to guess.

What antibiotics actually leave behind

The disruption isn’t subtle, and it isn’t always temporary. A May 2025 review in Cureus found that even after antibiotic treatment ends, certain microbial populations can fail to recover to their pre-treatment baseline, with lasting reductions in diversity and resilience. That’s not one bad week. That’s a gut that may be running a different ecosystem than the one you had before.

The mechanism is worth understanding, because it explains why “just wait it out” doesn’t always work. Researchers using whole-community imaging in mice found that the spatial relationships between bacterial species in the gut, essentially who lives next to whom, still hadn’t returned to baseline even 35 days after antibiotic exposure. Gut bacteria aren’t just individual species floating around; they form neighborhoods, and neighborhoods take time to rebuild, not just repopulate.

A few concrete things happen when you take a course of antibiotics:

• Species richness drops almost immediately, often within days of starting treatment

• Keystone species can disappear entirely, sometimes permanently, even when overall bacterial counts look normal again

• Short-chain fatty acid production falls, which matters because SCFAs feed your colon cells and help regulate inflammation

• Antibiotic resistance genes can persist or even rebound in the recovering population, a quieter, longer-tail risk than the diarrhea everyone worries about

• Recovery speed varies enormously by person, shaped by your starting microbiome, your diet, and which antibiotic you took

None of this means antibiotics were the wrong call, they’re not optional when you have a bacterial infection. It means the aftermath deserves a plan, not a shrug 🔬.

The probiotic paradox nobody warned you about

Here’s where it gets genuinely confusing, because the evidence looks contradictory until you separate two different questions.

Question one: do probiotics prevent diarrhea while you’re on antibiotics? Largely yes. Meta-analyses on two well-studied strains found that Lactobacillus rhamnosus GG and Saccharomyces boulardii can lower the risk of antibiotic-associated diarrhea by roughly half and shorten its duration by about a day. That’s a real, strain-specific benefit, and it’s the reason doctors sometimes suggest a probiotic alongside your prescription.

Question two: do probiotics speed up your gut’s return to its normal self after you finish? This is where it gets uncomfortable. A landmark study published in Cell put this to the test directly in both mice and human volunteers, comparing multi-strain probiotics, autologous fecal transplant (using a person’s own pre-antibiotic stool), and simply letting the gut recover on its own. The result: probiotics produced a markedly delayed and persistently incomplete recovery of the native gut and mucosal microbiome compared to spontaneous recovery, while the autologous transplant led to a rapid, near-complete recovery within days. In other words, the generic probiotic capsule may have been occupying the very niches your original bacteria needed to reclaim.

A 2025 mouse study out of NC State adds another layer: different probiotic strains can either accelerate or delay the gut microbiome’s recovery after antibiotics, which means “probiotics” is not one intervention, it’s dozens of them with opposite effects depending on the strain. And a fresh randomized trial published in January 2026 in the journal Antibiotics tested a 24-strain synbiotic (a probiotic paired with a prebiotic) taken during and after a ciprofloxacin and metronidazole course, and found it did promote recovery of microbial diversity, function, and gut barrier integrity, suggesting formulation and timing matter as much as the word “probiotic” on the label.

So what should you actually do? The NIH Office of Dietary Supplements is candid about this: there’s no official recommendation for probiotic use in healthy people, and choosing a strain, dose, or duration is genuinely an individual call, ideally with your doctor or pharmacist. If you’re trying to sort evidence-based options from marketing noise, we broke down which longevity supplements actually clear that bar in 5 Longevity Supplements That Aren’t Snake Oil.

Have you ever taken a probiotic during antibiotics on autopilot, without knowing whether it was helping or getting in the way? You’re far from alone 🧠.

Feed what survived: fiber, ferments, and the diversity gap

If probiotics are a mixed bag, what about diet? This is where a genuinely surprising 2021 Stanford trial reshaped how researchers think about gut recovery, and it’s worth walking through in detail because the finding cuts against conventional wisdom.

In a 10-week randomized trial, 36 healthy adults were assigned to either a high-fermented-food diet (yogurt, kefir, kimchi, sauerkraut, kombucha) or a high-fiber diet (legumes, whole grains, seeds, vegetables). The fermented-food group saw a significant increase in overall gut microbial diversity, with stronger effects at larger servings, while the high-fiber group’s microbial diversity remained essentially unchanged over the same window. Researchers had expected the opposite. Fiber is supposed to be the universal gut hero, but in a short time frame, it turns out you can’t feed microbes that aren’t there in sufficient numbers to expand.

That distinction matters enormously for post-antibiotic recovery. Fiber is still essential, it’s the long-game fuel for the bacteria you have left, and going without it will slow recovery further. But fermented foods appear to do something fiber alone can’t: they deliver live organisms and their metabolic byproducts directly, which may help re-seed a depleted ecosystem faster than diet alone. The Stanford research team’s own summary noted the diet also lowered several markers of inflammation, a secondary benefit worth having on its own.

Practically, that means leaning on both, in different roles:

• Fermented foods for re-seeding: plain yogurt or kefir with live active cultures, kimchi, sauerkraut (unpasteurized, refrigerated), miso, tempeh

• Prebiotic fiber for feeding: oats, onions, garlic, leeks, legumes, bananas, and other sources of inulin and resistant starch

• Polyphenol-rich foods like berries, olive oil, and green tea, which some of your surviving bacteria can metabolize into anti-inflammatory compounds

• Variety over volume: a wider range of plant foods each week tends to outperform eating more of the same few foods

We covered the broader habit-level version of this in 5 Easy Ways to Improve Gut Health for Better Longevity, if you want the everyday-maintenance version rather than the post-antibiotic sprint.

A rebuild plan that actually matches the evidence

Putting the research together, here’s a reasonable, evidence-anchored approach rather than a supplement-aisle guess:

• During treatment: if your doctor recommends a specific probiotic strain like LGG or S. boulardii to reduce diarrhea risk, that’s backed by solid meta-analytic evidence, take it as directed, spaced a couple of hours from your antibiotic dose

• First week after finishing: prioritize fermented foods over generic probiotic capsules unless your clinician has a specific reason to recommend one, and start reintroducing fiber gradually rather than all at once

• Weeks two through six: build fiber intake steadily, add polyphenol-rich foods, and keep the fermented-food habit going rather than treating it as a one-week fix

• Throughout: get enough sleep and manage stress, since both independently influence gut barrier function and inflammation, something we go deeper on in 6 Simple Ways to Lower Inflammation

• Avoid stacking multiple random probiotic products at once “just in case”, the strain-specific evidence doesn’t support a shotgun approach

Recovery timelines vary a lot person to person, but expect the process to run weeks, not days. That’s not a failure of your effort, it’s just how ecosystems rebuild.

What we still don’t know (and when to call a doctor)

We’d be overselling this if we implied the science is fully settled. It isn’t. We don’t have a reliable way to predict, ahead of time, which strain will help your specific gut versus someone else’s, which is exactly why the field is racing toward personalized, biomarker-guided probiotics rather than one-size-fits-all products. Living biotherapeutic products and engineered postbiotics are now in dozens of industry-sponsored trials, some head-to-head against fecal transplant for recurrent infections, and that landscape is moving fast. Want to know how this fits into the broader longevity picture, the companies, the competing trials, the money behind the science? LongevityHub Pro has that map.

There’s also a real medical risk worth taking seriously, separate from ordinary post-antibiotic bloating: C. difficile infection. Per the CDC, antibiotic use raises your risk of C. diff infection, and if you develop diarrhea while on or after taking an antibiotic, you should contact a healthcare professional to be evaluated, rather than assuming it will pass on its own. Watery diarrhea lasting more than two days, fever, or abdominal pain after a course of antibiotics isn’t something to self-treat with yogurt.

Your gut microbiome isn’t a switch you flip back on, it’s a garden you replant, one that rewards patience and specific choices over blanket assumptions. Which part of this plan are you actually going to try first: swapping the random probiotic for real fermented food, or finally tracking whether your gut symptoms line up with something worth calling your doctor about?

You used to bounce out of bed. Now you’re on your third coffee by 2pm, wondering if this is just what fifty, or forty, or honestly thirty-five, feels like now. Here’s the uncomfortable part: sometimes it is just aging, but far more often than people assume, it isn’t. 🧬 The National Institute on Aging is blunt about this: fatigue that sticks around for weeks is worth a doctor’s visit, not a shrug. We looked at what the research actually says separates ordinary tiredness from something with a real, identifiable cause, and what’s worth trying before you accept exhaustion as your new baseline.

The “just getting older” story usually isn’t the whole story

A striking number of common fatigue causes are boring, well-understood, and treatable once someone actually checks for them. Hypothyroidism slows nearly every metabolic process in the body and is diagnosed with a single blood test. Iron-deficiency anemia reduces how much oxygen your blood can carry to tissue, and it’s one of the more common reversible causes of chronic tiredness, especially in women. Low vitamin B12 does something similar by impairing red blood cell production and, over time, nerve function. 🩺 And sleep apnea is chronically underdiagnosed in older adults specifically, because “loud snoring” gets waved off as a personality trait instead of investigated as a medical problem.

Medications deserve a mention too, since they’re the cause people check last. Beta blockers, antihistamines, and sedatives can all produce fatigue as a side effect, and the effect compounds when someone’s on more than one.

• Ask for a thyroid panel (TSH, and free T4 if TSH is abnormal)

• Ask for a complete blood count and ferritin to screen for anemia

• Ask about B12 and folate levels, especially past age 50

• Bring up snoring, gasping, or witnessed pauses in breathing during sleep

• Review every medication and supplement with your doctor, not just the new ones

If you want the fuller rundown of which biomarkers are actually worth ordering, we mapped out seven of them in an earlier piece. Have you actually had a full panel run in the last two years, or are you guessing based on how you feel?

The biology behind “everything just feels harder now”

Once the obvious, checkable causes are ruled out, there’s a real mechanism left standing: mitochondrial decline. Mitochondria are the structures inside your cells that convert food and oxygen into usable energy, and their efficiency genuinely drops with age, marked by fewer functioning mitochondria per cell and impaired signaling for making new ones. 🔬

A 2016 study out of the University of Florida put this to a direct test. Researchers biopsied thigh muscle in 48 sedentary older adults (average age 72) and split them into fatigued and non-fatigued groups using a validated questionnaire. The fatigued group showed measurably lower mitochondrial content and suppressed levels of the proteins that regulate mitochondrial repair and renewal, without higher levels of oxidative damage to explain it. In plain terms: their cells had fewer working power plants, not more damage to the ones they had. This was an observational study, not a trial, so it shows correlation rather than proof that low mitochondrial content causes fatigue, but it’s a specific, human, biopsy-confirmed finding rather than a vague appeal to “cellular aging.” 🧠

• Mitochondrial content and biogenesis signaling both decline with age, independent of oxidative stress

• This decline shows up first as reduced exercise tolerance and slower recovery, not dramatic symptoms

• It’s a real biological process, but it isn’t a life sentence; the next section covers what actually moves the needle

The sleep you’re getting may not be the sleep you think you’re getting

Even people who technically sleep eight hours often lose something invisible: slow-wave sleep, the deep, restorative stage where growth hormone gets released and tissue repair happens. A landmark JAMA study tracking healthy men across adulthood found the percentage of deep slow-wave sleep drops from around 19% in early adulthood (ages 16 to 25) to roughly 3% by midlife (ages 36 to 50), with growth hormone secretion declining right alongside it. 😴 That’s not eight bad nights. That’s a structural shift in what sleep even accomplishes once you’re inside it.

This matters because two people can report the same number of hours slept and have completely different recovery from it. The one losing the most slow-wave sleep is going to feel it during the day, even with a full night logged.

• Consistent sleep and wake times protect the sleep architecture you still have

• Alcohol close to bedtime specifically suppresses slow-wave sleep, on top of everything else it disrupts

• Late, intense exercise can delay the deepest sleep stages for some people

• If daytime fatigue persists despite “enough” hours, sleep quality, not quantity, is the more useful thing to investigate

We went deeper on the actual mechanics of recovery, including why sleep outranks diet and exercise for some longevity outcomes, in our piece on why recovery is the most underrated longevity tool.

The fix that sounds backwards: move more when you feel like moving least

Here’s the part that annoys nearly everyone who’s exhausted: the best-supported non-medical fix for persistent fatigue is exercise, not rest. Chronic low energy tends to trigger a deconditioning cycle, tiredness leads to less activity, less activity lowers your actual physical capacity, and lower capacity makes ordinary tasks feel more exhausting, which produces more tiredness. 💪 Rest treats the symptom. Movement interrupts the loop.

A 2023 cluster-randomized trial out of Hong Kong tested this directly in 184 frail older adults, average age 79. One group got a 16-week individualized exercise program plus behavioral coaching to support adherence; another got the exercise program alone; a third got health talks only. The group with exercise plus coaching showed significantly lower fatigue scores, an effect that held up a full 12 months later. The exercise-only group, notably, didn’t differ significantly from the control group, which is a genuinely useful and slightly humbling finding: a generic “go exercise more” prescription without support for actually sticking with it may not be enough on its own. 🏋️

• Start smaller than feels meaningful; consistency beats intensity for breaking the deconditioning cycle

• Pair any new routine with something that supports adherence: a class, a partner, a coach, a calendar reminder

• Expect the first two to three weeks to feel harder before they feel easier

• Track fatigue and function, not just workouts completed, since that’s the outcome that actually moved in the trial

What about NAD+ boosters, then?

This is where LongevityHub has to be the annoying friend who won’t just tell you what you want to hear. NMN and NR, the supplements marketed to restore declining NAD+ levels and, by extension, cellular energy, have a genuinely solid biochemical rationale. NAD+ is central to how mitochondria produce energy, and levels do decline with age. 💊 But a 2026 systematic review covering 33 human intervention trials found that while NMN and NR reliably raise NAD+-related blood markers, their effects on actual functional, metabolic, and vascular outcomes were heterogeneous and often null. A separate 2025 meta-analysis of 10 randomized trials found no significant benefit for muscle mass, strength, or physical function specifically in older adults.

“The data in humans are pretty iffy right now that it actually has significant benefits,” is how one researcher put it to NPR earlier this year, and that’s a fair summary of where the evidence actually sits. We’ve covered NMN and other newly mainstream longevity compounds in more detail elsewhere, and the short version hasn’t changed much since: promising biochemistry, unproven functional payoff. If this story raised questions, who else is working on this, what the trial data looks like, which investors are behind it, LongevityHub Pro is where to find the answers.

• NAD+ precursors reliably raise NAD+ blood markers; that part is well established

• Functional benefits (energy, strength, fatigue specifically) remain unproven in rigorous human trials

• Short-term safety data looks reasonably favorable across the studies reviewed so far

• Treat these as an optional, monitored experiment, never a substitute for ruling out the causes covered above

Before you spend money on a supplement with unsettled evidence, have you actually ruled out the boring, checkable, well-documented causes first? That’s usually where the real answer is hiding.

Frequent flyers know the drill: another red-eye, another hotel gym you’ll skip, another Tuesday that starts at a gate instead of a desk. If you fly for work more than a few times a year, your body is running its own quiet experiment, and most of what you’ve heard about the results is wrong. The dramatic claim floating around wellness media, that cabin air is torching your cells with oxidative damage, doesn’t hold up well under actual lab conditions, according to a small hypobaric-chamber study out of Eurac Research. 🔬 What does hold up: immobility, dehydration, and circadian disruption, three mundane, well-documented mechanisms genuinely worth packing around. We went deep on the biology behind all of this in our breakdown of what long-haul flights actually do to your body. This is the shorter, practical version: what’s actually worth putting in your carry-on, and what you can skip.

Pack for your blood flow, not your comfort

Sitting motionless in an economy or even business-class seat for hours lets blood pool in your leg veins, the mechanism behind deep vein thrombosis (DVT). For a healthy traveler this risk stays genuinely low: symptomatic clots occur in roughly 27 per million passengers within two weeks of a flight, according to a summary of the evidence in American Family Physician. Quiet, symptomless clots are more common, showing up in an estimated 2 to 3% of higher-risk travelers.

Here’s the item actually worth packing: graduated compression socks. A 2021 Cochrane review pooling nine trials and more than 2,600 travelers on flights of five-plus hours found that only 3 people wearing stockings developed a symptomless clot, versus 47 who didn’t, high-certainty evidence for a real effect. 🩸 The catch, and it’s worth being straight about: none of the trials had enough events to say whether stockings reduce the rarer, more dangerous outcomes, symptomatic DVT, pulmonary embolism, or death, simply because those happened too infrequently to measure. Compression socks are cheap insurance with solid data behind the mechanism, not a guarantee against catastrophe.

The second item costs nothing: a phone reminder to move. Sitting still is the actual driver here, more than altitude or air quality. 🧬

• Graduated compression socks (below-knee, moderate compression) for flights over four hours

• A recurring hourly reminder to do ankle pumps or a short aisle walk

• Aisle seat if you have any personal risk factor, so getting up doesn’t require negotiation

• Flag pregnancy, recent surgery, hormone therapy, or a prior clot to your doctor before a long-haul trip

When was the last time you actually got up during a flight instead of telling yourself you’d do it at the next opportunity? ✈️

Protect the barrier that’s failing silently

Cabin humidity typically sits between 10% and 20%, well under the 30 to 60% range considered comfortable for your skin and airways. 🌵 Your skin barrier depends on water balance to stay elastic and intact, so in that dry air, water evaporates from the skin’s surface faster than normal, a process dermatologists call transepidermal water loss. By hour six you notice it as tightness, flaking, or that specific “airplane face” feeling. One flight won’t visibly age your skin. This is a cumulative story for people who fly often, not a single-trip emergency, but the mechanism behind it is real and worth planning around.

The oxygen side of this is more reassuring than the internet suggests. A 2007 New England Journal of Medicine study that put more than 500 volunteers through a simulated 20-hour flight found oxygen saturation dropped by roughly 4.4 percentage points at cabin-equivalent altitude, enough to cause mild discomfort in some people, not enough to trigger altitude sickness in most healthy travelers. It’s a real physiological shift, just a modest one. 💧

The fix here has nothing to do with expensive gadgets. It’s water, timed properly, and a barrier product that actually holds moisture in.

• A refillable water bottle you fill after security, not the tiny cup from the beverage cart

• An occlusive moisturizer (ceramides or petrolatum) applied mid-flight, not just at the gate

• Saline nasal spray to counter the dried-out mucous membranes that make you more prone to catching whatever’s going around the cabin

• Skip alcohol and heavy caffeine in flight; both worsen fluid loss on top of what the cabin air is already doing

Have you ever actually finished a full water bottle on a long flight, or just meant to? 🧴

Time your light and your melatonin, not just your flight

Jet lag isn’t really about the flight itself. It’s your circadian rhythm running on the wrong clock once you land, and the adjustment isn’t instant or symmetric. Bodies typically resync at roughly one and a half time zones per day traveling westward, but closer to one zone per day traveling eastward, part of why the flight home from Tokyo feels worse than the flight there. 🧠 Sleep duration tends to normalize within a couple of days; sleep timing can take a week or more to fully catch up, which is the gap between feeling fine and actually being recovered.

The best-supported tool here is unglamorous: melatonin, taken at the right time, in a smaller dose than most people assume they need. 🔬 A Cochrane review pooling ten randomized trials found doses between 0.5 and 5mg were similarly effective for flights crossing five or more time zones, with fast-release formulations outperforming slow-release ones. Timing matters more than dose. Taken at the wrong point in the day, melatonin can actually delay your adjustment instead of speeding it up.

This corner of circadian research moves fast, with new studies on hypoxia’s effect on melatonin release and cortisol landing every year. For the full intelligence picture behind developments like this one, LongevityHub Pro has you covered.

• Low-dose melatonin (0.5 to 3mg), fast-release, taken near your destination bedtime, not the moment you board

• Get outside into real daylight during local daytime hours on arrival, rather than hiding in a dark hotel room

• An eye mask and earplugs to protect sleep on the flight itself, especially on overnight legs

• For trips under three days, skip elaborate pre-shifting protocols; they often cause more disruption than they solve

If your evenings tend to unravel your sleep even at home, our 5-minute evening routine for circadian health is worth pairing with this.

What time zone actually governs your body right now, the one on your phone, or the one you left three days ago? 🌙

Track one number after you land

You don’t need a suitcase full of recovery gadgets. If you already wear something that tracks heart data, there’s one signal worth checking for a few days after a long flight: your resting heart rate. A meaningfully elevated resting heart rate for several mornings after landing is a simple, low-effort marker that your body is still catching up, whether from dehydration, poor sleep, or the accumulated stress of the trip itself. 📊

This isn’t about optimizing a dashboard of numbers you don’t understand. Most wearable metrics marketed at travelers are noise dressed up as insight, and we’ve broken down which ones are actually worth your attention elsewhere. Resting heart rate earns its spot because the mechanism is straightforward and the signal is hard to fake: your heart doesn’t lie about whether it’s still compensating for a rough 14 hours in a metal tube. 🧬

If your resting heart rate stays elevated for more than four or five days after a short trip, that’s less about jet lag and more a nudge to actually rest, not push through another packed itinerary the moment you land.

• Check resting heart rate on waking, before caffeine, for three to five days post-flight

• Compare against your personal baseline, not a generic population number

• Treat a multi-day elevation as a signal to prioritize sleep and hydration, not a red flag requiring a doctor

• Ignore single-day spikes; look for a pattern, not a blip

Do you actually know what your resting heart rate looks like on a normal week, or only during travel chaos? ❤️

Skip the cellular protection supplements at the airport kiosk

Airport shops and travel-wellness brands love to sell you pills promising to fight the oxidative damage supposedly inflicted by cabin air. Here’s the inconvenient truth for that entire product category: the underlying premise is shakier than the marketing suggests. Researchers at Eurac Research put twelve healthy volunteers through a hypobaric chamber simulating flight-altitude conditions, drew blood, and measured two established markers of oxidative stress. The result: no significant increase in either marker. 🔬 The study was small, and there was a slight upward trend in one marker among older participants specifically, which the researchers flagged as worth following up, not as proof of anything. Still, it’s a direct test of the exact claim these supplements are selling you, and the claim didn’t hold.

That doesn’t mean nothing you do on a flight matters. It means the mechanisms worth spending money on are the boring, well-documented ones: compression, hydration, timed light and melatonin. Antioxidant blends, cellular defense gummies, and portable oxygen canisters marketed for healthy travelers are solving a problem that the best available evidence says isn’t really there, at least not at the scale a single trans-Atlantic flight produces. 💊

• Skip antioxidant supplement blends marketed specifically for flying; the evidence for the problem they claim to solve is thin

• Skip portable oxygen canisters unless a doctor has specifically recommended one for a diagnosed condition

• Save the money for compression socks and a good moisturizer instead, both of which have real trial data behind them

• Stay skeptical of any product claiming to detox you from a flight; your liver and kidneys already do that job

None of this is about willpower or discipline. It’s about spending your limited carry-on space and your money on the four or five things with actual evidence behind them, and skipping the rest. What’s currently in your travel bag that’s never once been shown to do anything? 🧳

Nobody in their 20s wants to hear about bone density. You want a good coffee order, a job that doesn’t drain you, and maybe a decent night’s sleep after Saturday. Fair enough. But here’s the part almost nobody tells you: the body you’ll have at 50 is largely being built right now, quietly, whether you’re paying attention or not. Researchers at Stanford Medicine who study health across the lifespan put it plainly in a January 2026 report on habits for young adults: the earlier you start, the less damage you’ll have to undo later. 🧬 This isn’t about turning your 20s into a wellness retreat. It’s about five specific, evidence-backed habits, each with a real mechanism behind it, that are cheap to build now and expensive to rebuild after 40.

Lift something heavy, twice a week

Here’s a fact that surprises most people: your skeleton has a closing window. Peak bone mass, the maximum density and strength your bones will ever reach, typically arrives sometime between your mid-20s and age 30, according to the Mayo Clinic. After that, bone remodeling still happens, but you start losing slightly more than you gain. Think of it as a bank account you’re only allowed to deposit into for a couple more years 💰. Whatever balance you build now is roughly what you’re working with for decades.

The mechanism is mechanical, literally. When you load a bone with resistance, weights, your own bodyweight, resistance bands, it triggers bone-building cells to lay down more mineral. The same stress on muscle fibers kicks off muscle protein synthesis, the repair process that adds strength and size over time. 🏋️ Stanford’s Michael Fredericson notes that to actually build new muscle rather than just maintain what you have, you need to train close to fatigue, the point where one or two more reps feels genuinely hard. Lighter weights with more reps work fine, as long as you push to that point. Pairing training days with protein early in the day, as our longevity checklist covers in more detail, gives that repair process an extra nudge.

A quick myth check for anyone still hesitating: lifting weights will not make women bulky. It builds the bone density and strength that protects against fractures and osteoporosis decades down the line, which matters more than most 25-year-olds realize until it doesn’t.

• Aim for at least two resistance sessions per week, per current national guidelines

• Train close to fatigue, not just through the motions

• Compound movements (squats, presses, rows, lunges) recruit the most muscle and bone

• Bodyweight training counts if you push intensity

• Track progress every few months, not every session

Have you actually trained to fatigue this week, or just gone through the motions? 💪 The difference is the whole point.

Protect your sleep like it’s a job, not a leftover

If you’re pulling five or six hours a night during the week and calling it even with a Saturday sleep-in, the math doesn’t work. Research consistently shows you can’t fully repay chronic sleep debt with weekend recovery sleep. The metabolic and cognitive costs compound, according to Stanford’s Clete Kushida, MD, PhD, who helped author the sleep consensus guidelines used across the field. His recommendation is straightforward: more than seven hours, consistently, not just on your best nights.

This matters more than people assume. LongevityHub covered a 2025 analysis of CDC county-level data 🔬 from Oregon Health & Science University that found sleep had a stronger association with life expectancy than diet, exercise, or social isolation, second only to smoking. That’s not a small claim, and it’s worth sitting with: the thing you’re most likely to sacrifice for a late-night deadline or a second scroll through your phone might be the single biggest lever you have.

Quantity isn’t the whole story either. If you’re logging eight hours in bed and still dragging by 2pm, something’s off, possibly fragmented sleep, low REM, or an undiagnosed issue like sleep apnea, which affects more young adults than most people expect, especially those carrying extra weight. 😴 More than 50 million Americans have a diagnosable sleep disorder, and most don’t know it. 🧠

• Keep a consistent wake time, weekends included

• Get morning light exposure within an hour of waking

• Cut screens, alcohol, and hard workouts in the hour before bed

• Consider a wearable to check actual sleep stages, not just hours logged

• If you’re rested in hours but not in how you feel, ask a sleep specialist

Building this now, while your schedule is relatively flexible, is a lot easier than retrofitting it once actual obligations pile on.

Build real-world social ties before you think you need them

Loneliness research used to focus almost entirely on older adults living alone. That’s changing fast, and not in a good way for anyone under 40. The WHO Commission on Social Connection estimates that social isolation and loneliness contribute to roughly 871,000 deaths a year worldwide, and found that loneliness is actually most common among adolescents and young adults, around 1 in 5, not retirees.

A long-running Norwegian study tracking over 17,000 adults aged 25 to 69 found something genuinely counterintuitive: the mortality risk tied to social isolation was actually higher in adults under 50 than in older participants. 🧠 Researchers aren’t fully sure why, but one plausible explanation is that isolation in early adulthood tends to be more chronic and less buffered by the kind of accumulated community ties people build later. Either way, the pattern challenges the assumption that this is only a problem for later decades.

The mechanism runs through the same stress pathways as chronic psychological stress. Perceived isolation keeps cortisol elevated, which over years affects cardiovascular and immune function. 🤝 It’s not really about being introverted or extroverted, quality of connection matters more than headcount.

• Prioritize a handful of people you see or talk to regularly, not a big network

• In-person contact beats digital contact for the physiological benefits

• Community groups, sports leagues, or volunteering build low-effort recurring contact

• Check in on people proactively rather than waiting to be invited

• Treat social plans with the same non-negotiable status as a workout

The WHO’s Commission report only came out in 2026, and researchers are still working out which interventions help most at which age. For the full intelligence picture behind developments like this one, LongevityHub Pro has you covered.

When’s the last time you called someone instead of texting them? It sounds trivial, and it isn’t. 📞

Eat for the metabolism you’ll have at 50, not just tonight

The CARDIA study, a Stanford-affiliated project that has followed more than 5,000 young adults for over three decades, found that people who ate less fast food and ate more of a plant-forward diet between ages 18 and 30 had measurably lower rates of cardiovascular disease and insulin resistance by middle age. 🥦 That’s not a study about someday. It’s about what’s on your plate this week showing up on a lab report in your 40s.

The practical version of this doesn’t require perfection. Stanford researchers point to the Mediterranean diet, plants, whole grains, healthy fats, lean protein, as the pattern with the best track record for lowering chronic inflammation. Protein specifically gets a lot of attention in longevity circles, and here’s where the evidence gets genuinely mixed: mainstream guidance suggests roughly 0.8 to 1.0 grams per kilogram of body weight daily, while some longevity researchers argue for less protein before 65, closer to 0.7 grams per kilogram, because higher intake chronically activates mTOR, a cellular growth pathway some evidence links to faster aging. Neither camp has this fully settled. If you’re strength training seriously, you likely need more protein, not less, so context matters more than a universal number.

Alcohol is worth a straight answer too: current guidance caps it at one drink a day for women and two for men, and less is generally better for long-term risk. 🍷

• Fill half your plate with vegetables and fruit before anything else

• Choose whole grains over refined carbs most of the time

• Hit a protein target that fits your activity level, not a generic number

• Cut back on ultra-processed foods high in added sugar and sodium

• Cook at home more often than not; it’s the single biggest lever for actual adherence

None of this requires an app or a subscription. It requires deciding, this year, that convenience food is the exception and not the default. 🥗

Learn to calm your body before your mind catches up

Your 20s can be relentless: career pressure, financial uncertainty, relationship decisions, maybe a move across the country, maybe a family starting. Telling yourself you’ll deal with the stress once things calm down is a reasonable instinct and also, according to research from Stanford’s David Spiegel, backwards. Chronic stress keeps cortisol elevated and blood pressure up long after the original problem is a memory, and those changes accumulate. 🔬

Spiegel’s research approaches this from an unusual angle: working from the body up, not the head down. Instead of trying to think your way out of stress by solving every problem first, techniques like deep breathing, meditation, and self-hypnosis calm the physiological response directly, which then makes the actual problem-solving easier. His studies on self-hypnosis found people reported meaningfully less pain and stress, with effects lasting years, not weeks. 🧘

This isn’t about ignoring real problems. It’s about not letting your nervous system stay in threat mode while you figure them out. And if stress tips into something heavier than “stressed out,” persistent hopelessness or feeling worthless, that’s a signal to talk to a professional, not a habit to push through alone.

• Practice a specific technique (breathing, meditation, self-hypnosis) regularly, not just in a crisis

• Build in movement, sleep, and reduced alcohol as stress-management tools too, not separate categories

• Notice physical stress signals early: tight jaw, shallow breathing, poor sleep

• Give the calming technique a few weeks before judging whether it works

• Seek professional support if stress becomes something closer to despair

Five habits, one thread running through all of them: biology rewards what you start early. None of this demands perfection, and nobody expects you to overhaul your life this weekend. Pick one habit from this list and give it 90 days. What would your body thank you for a decade from now if you started today? 🧬

If you’ve ever snapped at someone over nothing and later realized you just hadn’t eaten in six hours, you weren’t imagining it. A 2022 study published in PLOS ONE tracked 64 adults for three weeks, pinging them five times a day to rate their hunger and mood. Hunger alone explained 56 percent of the variation in how irritable people felt at any given moment. That’s not a small effect. That’s most of the story.

So if your first attempt at time-restricted eating (TRE) left you snapping at your coworkers by 11 a.m., the problem probably wasn’t willpower. It was the protocol. 🍽️ This guide is for people who want the metabolic upside of eating on a schedule without turning into someone nobody wants to be around. We’re going to build you a version that respects your blood sugar and your temper.

Hangry is a real, measurable thing, not a character flaw

Here’s the mechanism, briefly. When you go too long without eating, blood glucose drops, and your brain (which burns through roughly a fifth of your resting energy despite being a small fraction of your body weight) starts running on fewer resources. Your body responds by releasing cortisol and adrenaline to nudge glucose back up, and those same stress hormones are tightly linked to irritability. At the same time, the hunger hormone ghrelin rises, and it doesn’t just make you want food, it’s been tied directly to increased impulsivity in lab studies. 🧠

This is where fasting protocol matters more than fasting duration. A well-controlled 2019 trial in adults with overweight, published in the Journal of Clinical Endocrinology and Metabolism, compared eating from 8 a.m. to 2 p.m. against eating from 8 a.m. to 8 p.m., same total calories, same food. The early-eating group had lower ghrelin and hunger that stayed more even-keeled across the day, rather than spiking. Only 11 people, so treat it as a strong signal rather than proof, but it points somewhere specific: when you fast changes how hungry you feel, almost as much as how long you fast does.

• Low blood sugar triggers cortisol and adrenaline, both linked to irritability

• Ghrelin rises during extended fasting and is tied to impulsivity

• Early eating windows blunt this response more than late ones

• Individual variation is real. Some people genuinely tolerate longer fasts better than others

Start wider than you think, not narrower

Every fasting influencer wants you at 16:8 by Tuesday. Skip that advice. Satchidananda Panda’s lab at the Salk Institute tracked 156 adults using a food-logging app and found the average American eats across a window of 14 hours and 45 minutes a day, with fewer than 10 percent of people naturally eating within 12 hours or less. That’s the actual baseline you’re working from, whether you realize it or not.

Which means your first real win is compressing to 12 hours, not white-knuckling to 8. If you finish dinner at 8 p.m. and skip the 11 p.m. snack, then delay breakfast until 8 a.m. instead of 6 a.m., you’ve already hit a 12-hour window and you probably didn’t notice the change. We covered this exact easing-in approach in our roundup of longevity habits that sound stranger than they are, and it holds up here: consistency beats intensity.

Once 12 hours feels unremarkable, and only then, consider narrowing further. A 2024 randomized trial from UC San Diego and Salk, led by Panda’s group, put 108 adults with metabolic syndrome on a 10-hour window for three months and found meaningful improvements in blood pressure and cholesterol without loss of muscle mass. That’s a real result. It’s also a much gentler ask than the 16:8 protocols most beginners try first, and it’s worth noting the NIH’s own summary of this research is careful to say results across the broader field of TRE trials have been mixed, not universally positive.

Move your window earlier, not just narrower

If you only change one thing, change this. A tightly controlled 2022 crossover trial from Brigham and Women’s Hospital put 16 adults through identical meals, identical sleep, identical activity, on two schedules that differed only by four hours. Eating later doubled the odds of feeling hungry across the day, pushed the ghrelin-to-leptin ratio hard toward hunger, and even slowed daytime calorie burn. Same food. Same amount. Just shifted later on the clock, and hunger nearly doubled.

Be honest with yourself here: if your eating window currently runs from noon to 8 p.m., that’s the exact shape this study found produces more hunger, not less. An earlier window, roughly 8 a.m. to 4 or 5 p.m., or even 9 to 6, works with your biology instead of against it. We’ve also written about why an earlier eating window helps weekend recovery specifically, if Saturday mornings are where your schedule tends to slip.

• Aim for your last bite 3+ hours before bed

• Front-load protein and calories toward the earlier half of your window

• If you must choose between skipping breakfast or skipping dinner, the research favors keeping breakfast

• Give any new window at least 10 to 14 days before judging how you feel

Break your fast on purpose, not on autopilot

The moment you’re most likely to overeat, or crash an hour later, is the first meal after a fast. Hitting that window with black coffee and then a bagel sets you up for a glucose spike followed by a glucose crash, which is basically a hangry trap you built yourself. 🔬 Break the fast with something that has actual staying power.

• 25 to 35 grams of protein (eggs, Greek yogurt, a protein shake)

• Fiber alongside it (berries, vegetables, a piece of fruit) to slow the glucose response

• A source of fat, which further blunts how fast that first meal hits your bloodstream

• Water and electrolytes before the first meal, since mild dehydration mimics hunger and makes people reach for food they don’t actually need

• Skip the giant fasted workout right before breaking your fast unless you already know your body tolerates it well

Know what TRE will and won’t do for you

Here’s the part that gets buried under all the enthusiasm: for pure weight loss, the evidence that TRE beats plain old calorie counting is genuinely weak. A 139-person, 12-month randomized trial published in the New England Journal of Medicine compared an 8 a.m. to 4 p.m. eating window plus calorie restriction against calorie restriction alone. The TRE group lost slightly more weight on average, 8.0 kg versus 6.3 kg, but that difference wasn’t statistically significant (p=0.11). A separate 2025 trial in the journal Obesity found 12 weeks of self-selected 8-hour TRE didn’t produce clearer metabolic improvements than calorie restriction either.

So why bother? Because for a lot of people, TRE isn’t really a weight-loss tool, it’s an adherence tool. Not counting calories, just picking a window, is simply easier for many people to sustain, and sustained beats optimal every time. There’s also a separate, more mechanistic case for it involving autophagy, your cells’ internal cleanup process, which we broke down in more depth in our piece on the biological hallmarks of aging. If you’re the type of reader who wants to track every new trial in this space as it reports out, rather than waiting for a single headline to sum it up, LongevityHub Pro has you covered.

One honest caveat before you start: if you have any history of disordered eating, TRE can sometimes tip into restriction that doesn’t stay contained to a clock. Check in with yourself, or a doctor, if the eating window starts to feel less like structure and more like control for its own sake.

So, where does your current eating window actually sit right now, and is it closer to 12 hours or 15? That’s the honest starting point, not whatever protocol went viral this week.

The FDA still doesn’t recognize “aging” as a disease you can get a prescription for. That single fact shapes everything in this article: every drug below is technically being tested for a specific condition (an eye disease, obesity, cognitive decline), even though the researchers behind it are explicitly chasing something bigger. A 2025 systematic review from George Washington University put it plainly: the human evidence for most of these approaches “remains unestablished.” We agree with that framing, and we’re going to hold onto it through all five entries.

So this isn’t a hype list. It’s five drugs currently in human trials, real ones, with real participant counts, that target the biological processes researchers believe actually drive aging. We’ll tell you the mechanism, the study size, whether it’s academic or company-funded, and how far it realistically is from your medicine cabinet. 🧬

A gene therapy trying to rewind cells in the human eye

In June 2026, a Boston company called Life Biosciences dosed the first human participant with ER-100, a gene therapy built around partial epigenetic reprogramming. The mechanism, in plain terms: instead of turning old cells all the way back into stem cells (which risks cancer), the therapy nudges specific chemical tags on DNA back toward a younger pattern, aiming to restore function without erasing the cell’s identity. It’s delivered directly into one eye and activated by an oral antibiotic over eight weeks. 🔬

This is a Phase 1 trial, meaning the goal right now is safety, not proof it works. Up to 18 people will be enrolled, split between glaucoma and a stroke-like optic nerve condition called NAION. Worth flagging plainly: co-founder David Sinclair, the Harvard geneticist whose lab pioneered this reprogramming theory, is also the company’s public face, which is a real conflict of interest worth keeping in mind whenever a founder is also the loudest advocate for the science.

• Mechanism: partial epigenetic reprogramming (Yamanaka-factor-adjacent, but incomplete on purpose)

• Study size: up to 18 participants, Phase 1

• Funded by: Life Biosciences (the drug’s own maker)

• Realistic timeline: years away from anything beyond the eye, if it works at all

If it’s safe and the eye responds, the company has said it wants to move toward the liver and eventually other organs. That’s a big if, stacked on another big if.

Rapamycin moves from off-label buzz to actual trial data

Rapamycin is the drug longevity forums have been buzzing about for a decade, an old immunosuppressant that reliably extends lifespan in mice, worms, and flies by blocking a growth-signaling pathway called mTOR. The gap has always been human proof, and 2025 finally delivered some. The PEARL trial, a 48-week randomized, placebo-controlled study of 114 adults aged 50 to 85, tested weekly doses of 5 mg or 10 mg against placebo. Published in the journal Aging in 2025, it found the drug safe and well tolerated, with the standout signal being a roughly 6 percent gain in lean tissue mass among women on the higher dose. It did not measure lifespan, and it wasn’t built to. Be honest with yourself about what that means: safety and a lean-mass signal are real findings, but they’re a long way from “slows aging.”

We’d be doing you a disservice not to flag the funding here. PEARL was run by AgelessRx, a telehealth company that prescribes rapamycin, and crowdfunded in part through the advocacy group lifespan.io. That doesn’t make the data wrong, but it’s a company with a direct commercial interest in a positive result, which is exactly the kind of thing we think you deserve to know before reading too much into it.

Meanwhile, a genuinely independent trial is quietly running right now: Columbia University is testing whether low-dose rapamycin can delay ovarian aging in perimenopausal women, a randomized, triple-masked Phase 2 study that’s currently active. It’s a much narrower question than “does this drug slow human aging,” but it’s the kind of tightly scoped, academically run trial this field needs more of.

• Animal evidence: strong and repeatedly replicated across species

• Human evidence: one 48-week RCT, safety-focused, funded by a company that sells the drug

• Ongoing independent work: a Columbia University trial on ovarian aging specifically

• Bottom line: promising, unproven, and worth watching rather than acting on

A senolytic eye drug is already showing results in people

Here’s where the data gets stronger, at least for one narrow use case. Senolytics are drugs designed to clear out senescent cells, the “zombie cells” that stop dividing but refuse to die, instead pumping out inflammatory signals that damage the tissue around them. Foselutoclax (also called UBX1325), made by Unity Biotechnology, is a small molecule that blocks a survival protein these zombie cells depend on.

Two separate trials in diabetic macular edema, a leading cause of blindness, have now reported results. The Phase 2 BEHOLD study, 65 participants, found a single injection improved vision by an average of 6.2 letters on a standard eye chart at 48 weeks, a significant edge over sham treatment. The larger Phase 2b ASPIRE trial, 52 participants who’d already failed standard anti-VEGF treatment, found the drug held its own against aflibercept, the current gold-standard therapy, through 36 weeks. Both trials were published in peer-reviewed journals, including NEJM Evidence. 💊

This is company-funded research (Unity Biotechnology makes the drug), so treat the topline numbers with the same healthy skepticism you’d apply to any sponsor-run trial. But this is also, genuinely, the most mature clinical evidence on this list that a senolytic mechanism does something measurable in real human tissue. The catch: it’s a local injection into the eye, not a systemic anti-aging pill, and Unity is still working out what comes next for the broader program.

The systemic senolytic combo everyone’s biohacking, now in real pilot trials

If foselutoclax is the narrow, well-funded senolytic story, dasatinib plus quercetin (D+Q) is the messy, grassroots one. This combination, a repurposed leukemia drug paired with a plant flavonoid supplement, has become the most self-administered senolytic protocol among longevity enthusiasts, largely because both ingredients are already available. The actual clinical evidence is much thinner than the enthusiasm.

A 2025 pilot study published in eBioMedicine gave older adults at risk for Alzheimer’s disease two days of D+Q every two weeks for 12 weeks. It found the treatment feasible and safe, with a small, not-quite-significant bump in cognitive scores. A separate Phase 1 trial in people already diagnosed with Alzheimer’s, published in Neurotherapeutics, found almost no significant biomarker changes and, honestly, no real suggestion the drug was doing much of anything for that population. 😐 A third pilot, currently recruiting through Washington University in St. Louis, is testing the same combination in people with schizophrenia and treatment-resistant depression, on the theory that these conditions involve accelerated biological aging.

• What it targets: senescent cells throughout the body, not one organ

• Human evidence so far: multiple small, mostly academic pilot studies (n=20 to 30)

• What we’ve seen: safety and feasibility confirmed, meaningful efficacy not yet shown

• Funding: largely NIH and university-backed, less commercial conflict than most entries here

We’ll say it plainly: the animal data on D+Q is genuinely compelling, and the human safety data is reassuring. The human efficacy data, so far, just isn’t there yet. Anyone taking this off-label right now is running ahead of the evidence, not following it.

A drug built to calm the inflammation that drives aging itself

Our last pick is the newest to enter human testing. BGE-102, made by BioAge Labs, targets a protein complex called NLRP3, a central driver of inflammaging, the low-grade, chronic inflammation that climbs steadily with age and is linked to everything from heart disease to cognitive decline. Early Phase 1 data, presented in mid-2026, showed the drug cut a key inflammatory marker called hsCRP by a median of roughly 85 percent in people with obesity and elevated baseline inflammation. That’s a striking number for an early trial, though hsCRP is a biomarker, not a disease outcome, and biomarker drops don’t always translate into people actually feeling or living better. 🧠

BioAge dosed the first participant in a larger Phase 2 trial called QUELL-CV this past June, testing three doses against placebo in roughly 160 adults, with results expected later this year. It’s worth mentioning that this isn’t the company’s first attempt at a metabolic-aging drug: their earlier candidate, azelaprag, was discontinued in early 2025 after some participants showed liver enzyme elevations, a reminder that even well-funded, scientifically sound programs fail on safety grounds regularly in this field. That kind of course correction is normal drug development, not a scandal, but it’s exactly the sort of detail that gets left out of the more breathless coverage of this space. If you’re the type of reader who wants to track which companies are running which trials as these programs shift, LongevityHub Pro is where we keep that picture updated as it changes.

• Mechanism: NLRP3 inflammation pathway inhibition

• Early signal: ~85% median reduction in hsCRP, Phase 1, company-reported

• Current trial: QUELL-CV, Phase 2, ~160 participants, dosing since June 2026

• Funded by: BioAge Labs, the drug’s own developer

None of these five drugs are close to a prescription you can ask your doctor for tomorrow. We’ve covered rapamycin’s off-label rise before, and if you want the wider menu of drugs researchers are chasing for lifespan extension, we broke down six other medications under investigation in an earlier piece, alongside a look at the clinics already offering some of these therapies abroad if you’re curious how far ahead of the FDA some people are already moving.

Which of these five would you actually want to see published results on first? For our money, it’s whichever one finally forces the FDA to sit down and define what “aging” even means as a treatable condition. Everything else is downstream of that fight.